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                                                          ABSTRACT 
 
A STUDY OF MYCOPHENOLATE AND STEROIDS IN IGA 
NEPHROPATHY 
 
Department of Nephrology 
 
Dr.Vamseedhar.P.S 
 
( D.M.) , Nephrology 
 
Guide : Dr. V.Tamilarasi , MD,DM ( Neph.) 
 
 
 Aim: IgA Nephropathy (IgAN) has a rapid course in the Indian population. This case 
control study was performed to study mycophenolate (MPA) in high risk IgAN. 
 
 Methods: 41 IgAN cases at high risk of progression (24 hour proteinuria >3grams or e 
GFR(MDRD) <60ml/min/1.73m2 or mean arterial pressure (MAP) >=107mmHg or 
glomerulosclerosis involving >=50% of glomeruli) who were treated with MPA (dose 
controlled with therapeutic drug monitoring) and steroids +/- ACE-I/ARB were compared 
to two historical control groups, one that received steroids+/- ACE-I/ARB (control 1, 
n=31) and the other, without immunosuppression +/- ACE-I/ARB (control 2, n=41). 
 
 Results: Baseline characteristics of 3 groups were similar with respect to age, sex, MAP, 
proteinuria whereas e GFR in control 1 was higher by 15 ml/min. (p=0.03). Mann-
Whitney test was used. In cases, control 1 and control 2, after 3 months of treatment, 
median percent change in e GFR was 16.93,11.62, -8.23, %change in s. creatinine was -
12.5,-1.17,-1.32 and %change in proteinuria was -58.76, -45.31 and -48.53 respectively. 
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When cases were compared to control 2, there was a significant improvement in e GFR 
and s.creatinine (p=0.004 and 0.005) respectively, whereas there was a trend towards 
improvement in proteinuria in cases by 10% (p=0.313).On comparing cases to control 1, 
there was a trend towards improvement of proteinuria and e GFR  in cases by 13% 
(p=0.548) and 5% (p=0.58) respectively. Sub group analysis of patients in the 3 groups 
who received ACE-I/ARB revealed similar trends. 
 
 Conclusions: In high risk IgAN patients, MPA+steroids+ACE-I/ARB was beneficial 
with respect to improvement in renal function when compared to ACE-I/ARB alone and 
there was a trend towards better renal function when compared to steroids + ACE-I/ARB. 
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Review of literature
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IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis in the 
developed world and it is an important cause of end stage kidney failure [1,2]  
 
History of IgA Nephropathy (Berger’s Disease) –  
         The idea of using fluorescent-labeled specific antibodies to detect proteins in tissue 
was introduced by Coons and Kaplan[3] in 1950 and was first used for evaluation of 
diseased renal tissue by Mellors and Ortega[4] in 1957. 
        Percutaneous renal biopsy was initially described as a technique to diagnose kidney 
disease by Iverson and Brun in 1951 [5] . 
        Tomasi  et al. had discovered the IgA immune system in 1965 [6]. 
        Thus two techniques, immunofluorescent tagging of antibodies to detect antigens in 
tissues and percutaneous renal biopsy, along with the discovery of a new 
immunoglobulin present in serum and in tissue secretions (IgA) all paved the way for the 
seminal observations , beginning in 1967 of Jean Berger and Nicole Hinglais at the 
Necker Hospital in Paris, France concerning a new entity they subsequently called 
mesangial IgA/IgG deposition . They described their novel observations in a brief paper 
published in 1968 which described predominant IgA mesangial deposition in some renal 
biopsies where the immunostaining of IgA strongly outshone the IgG reagent. This was 
the discovery of  IgA nephropathy, also subsequently called Berger’s disease [7] . 
     The different names of IgA nephropathy are  -   
1. Nephropathy with mesangial IgA-IgG deposits 
2. Les glomerulopathies primitives a depots mesangiaux d’IgA et d’IgG 
3. Diffuse intra- und extrakapillare Glomerulonephritis mit IgA-Depots 
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4. IgA-IgG-Nephropathie 
5. Glomerulites a depots d’IgA diffuse dan le mesangium 
6. IgA-associated glomerulonephritis 
7. IgA nephropathy 
8. IgA-IgG deposits nephritis 
9. Immunoglobulin A glomerulonephritis 
10. Primary glomerulonephritis with mesangial deposits of IgA 
11. Benign hematuria-loin pain syndrome 
 
Epidemiology and Ancestral Difference :  
        Deposition of IgA is present in 4%–16% of normal, healthy living adults and 
cadaveric donors , the significance of which is not completely understood . Thus, from the 
epidemiological perspective, the biopsy-proven IgAN cases represent a very small fraction 
of the total individuals with such deposits in the population as a whole [8,9] .   
         In 1988 Levy and Berger outlining the “Worldwide perspective of IgA nephropathy” 
suggested that the apparent geographic variations in the percentage of this 
glomerulonephritis in kidney biopsy specimens could reflect different clinical policies for 
diagnostic tests more than a real ancestral difference [10] . 
          The systematic screening of urine samples could have influenced the higher 
prevalence reported both in Japan and in Singapore, the rare detection of IgAN in blacks 
either from the United States or from Africa was to be ascribed to the infrequent 
performance of biopsies in African patients with only microscopic hematuria and the 
frequent absence of immunofluorescence applied to renal biopsy [11 , 12 ]. 
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           While on one hand they were quite attentive to this primary aspect,they also got the 
hint that ancestral differences could suggest a possible role of genetic factors in the 
etiology of IgAN. 
           The clinical onset of IgAN is usually found in the second and third decade of life but 
may occur at any age. Males are affected from two-fold in Japan, to six-fold more than 
females as reported in Europe and in the United States. The disease is more frequent in 
Whites and Asians than in Blacks from United States and South Africa, but the explana- 
tion of this difference is still unknown. 
       Most of the worldwide studies report prevalence rates as a percentage of cases of 
primary glomerulonephritides or as a percentage of a total series of renal biopsies, while 
few epidemiologic studies focused on the real incidence of primary IgAN in various 
populations [13]. 
        An interesting study by Geddes  et al. aimed at examining four IgAN databases from 
four different countries in three continents to determine if geographic variability in long 
term outcome is independent of renal function, proteinuria and blood pressure at the time of 
diagnosis. They included patients from Glasgow (United Kingdom), Helsinki (Finland), 
Sydney (Australia) and Toronto (Canada). The results supported the hypothesis that the 
variation in the rate of progression of renal disease was probably due to variability at 
presentation in both duration (lead-time bias) and severity of disease in different countries. 
They did not exclude the possibility that true geographic variability exists mainly because 
of genetic variability, but also because of environmental factors, including dietary 
differences between countries. The geographic variability is responsible for difference in 
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ten year renal survival in patients with IgAN ranging between 95.7% in Helsinki and 
61.6% in Toronto [14]. 
         The role of environmental antigen triggers together with a genetic susceptibility 
factor determining the onset of the disease is still under debate. The higher prevalence of 
IgAN in Asian/Pacific Islanders could be supported by the evidence that high intake of rice 
and n-6 poly-unsaturated fatty acids could be associated with an increased risk of the 
disease as reported by Wakai et al. [161] or by the suggested role of Hemophilus 
parainfluenzae as a causative agent of the disease in Japanese individuals [15 , 16 ,17 ]. 
              
Worldwide Distribution 
Europe : 
     The incidence of IgAN in  Italy is 8.4 patients per million population(pmp) per year. 
According to the Italian Registry of Renal Biopsies (IRRB), based on data related to 32,862 
renal biopsies collected during the years 1987–2000 from 128 renal units in Italy, IgAN is 
the most frequent disease among primary glomerulonephritides (21.5%) and its frequency 
is higher in males (39.3%) than in females (27.8%) (http://www.irrb.net). 
    The disease is also the most common primary glomerulopathy in Germany. 
     In a study of renal biopsies between 1970 and 1986, with a sample size of 8545 cases in 
adults and 1364 in children, Rivera  et al. described the high incidence of IgAN and the 
decrease of membranoproliferative glomerulonephritis in  Spain. The mean annual inci- 
dence (pmp) of the disease was 7.9, making the disease the most common primary 
nephropathy [18]. 
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America : 
     In Brazil, IgAN (29.4%) is the most frequent disease diagnosed among non-nephrotic 
patients. An increase in frequency of focal and segmental glomerulosclerosis has been 
reported in non-nephrotic patients; thus this disease became as common as IgAN (31.6% 
and 28.0%, respectively) from 1994–1999 [19] . 
       The most common primary glomerular disease in San Paolo is focal and segmental 
glomerulosclerosis (29.7%), followed by membranous nephropathy (20.7%) and IgAN 
(17.8%), confirming the above data [20] . 
         The United States Renal Data System (USRDS) reports that 0.8% of incident end 
stage renal disease patients in the  USA  have documented or suspected IgAN 
(http://www.usrds.org.) . 
           In a 30-year renal biopsy study in Olmsted County (Minnesota), IgAN was present 
in 22% of biopsy-proven patients, thus representing the most frequent glomerulonephritis 
[21]. 
          In 2006, Nair and Walker examined if IgAN still remained the most common 
primary glomerulopathy among young adults in the USA. In their study from a large renal 
biopsy referral center serving  Midwestern and Southern states they grouped the patients in 
adults (≥ 20 years) and young adults (20–39 years). The disease was the most common 
primary glomerulopathy in young adult Caucasians (with a ratio IgAN/focal segmental 
glomerulosclerosis of 2.1:1) and also the most common cause of end-stage renal disease in 
this race. On the contrary, the disease was rare in African Americans in whom focal seg- 
mental glomerulosclerosis remains more common (focal segmental 
glomerulosclerosis/IgAN 9.7:1) [22] . 
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Australia : 
      In a retrospective review of the pathology reports of all native renal biopsies performed 
in the state of Victoria, Australia, the most common glomerulonephritis in adults in 1995 
and 1997 was IgAN (10.5 per 100,000 individuals). The disease accounted for 34.1% of all 
biopsy proven glomerulonephritides and was also the most common cause of end-stage 
renal disease due to glomerulonephritis [ 23 ] . 
  
Asia : 
       Renal biopsy has been routinely performed in China in the last 20 years and IgAN is 
the most common primary glomerulonephritis occurring in the largest Asian country, 
representing 45.3% of the primary glomerulonephritides. The disease is also the leading 
cause of end stage renal disease, accounting for approximately 18% of patients [ 24 , 25 ].         
It has also been reported at a frequency of 35% in Hong Kong by Lai and 34% in 
Singapore by Sinniah in the 1980s  [26] . 
         In Korea, in a study on a total of 4514 cases of renal biopsy collected over a 23-year 
period between 1973 and 1995, the most common primary glomerulonephritis in adults was 
minimal change disease (26.6%), followed by IgAN (22.1%) [27] . 
         The disease is listed as the primary cause of end stage renal disease in 28% of new 
dialysis patients as reported by Koyama  et al. in a national survey of Japanese patients 
[28]. 
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       The Research Group on Progressive Chronic Renal Disease, in their Nationwide and 
long-term survey of primary glomerulonephritis in Japan, found that 47.4%  of 1045 biopsy 
specimens examined by immunofluorescence microscopy were IgAN [29]. 
       In a retrospective analysis of 1592 renal biopsies received from various hospitals all 
over Kerala (India) over a period of two years, Chandrika observed that of the 1544 native 
kidney biopsies, the majority of cases (18.84%) were focal segmental glomerulosclerosis 
followed in frequency by IgAN (14.26%) [30] . 
         
Genetic Contribution to IgA Nephropathy : 
        Several lines of evidence support a contribution by genetic factors to the development 
of, or susceptibility to, overt IgAN –  
       1. Many pedigrees have been described in which more than one individual is affected 
by IgAN. In some of these, genetic loci have been identified by linkage analyses[31,32,33]. 
        2. There are differences in prevalence in ethnically different populations which are 
unlikely to be fully accounted for by differences in environment and ascertainment [34]. 
       3. First and second degree relatives of IgAN patients have higher relative risks of 
developing this disease compared to the general population [35]. 
      Most cases of IgAN are “sporadic” rather than familial. IgAN is therefore  generally 
considered to be a complex disorder, i.e. it is a multifactorial  disease with both genetic and 
environmental factors . However, in some families the disease segregates in an obviously 
autosomal dominant fashion. It therefore seems likely that the genetic contribution to the 
disease is heterogenous, and can lie anywhere in the spectrum from monogenic, through 
oligogenic to polygenic. 
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       Using linkage analysis, several loci have been implicated in IgAN in different 
pedigrees -  2q36 locus, 6q22-q23 (IGAN1) and 3p24-p23 loci, 4q26-q31 (IGAN2) and 
17q12-q22 (IGAN3) loci. The relative risk of IgAN is 16 times higher in first degree 
relatives (parents and siblings), and more than two-fold increased in second degree 
relatives (grandparents, grandchildren) of index cases compared to the general population 
[35]. Some genetic variations may contribute to more rapid progression of the disease . 
There is some evidence that variants in ACE (Angiotensin I converting  enzyme I) [36] and  
AGT (Angiotensinogen) alter response to ACE inhibitors and/or angiotensin receptor 
blocker [37]. 
      
 
Histopathology, Immunofluorescence and Ultrastructural Examination :  
      Primary IgAN is a chronic glomerulonephritis defined by the presence or deposition in 
the mesangium of predominant IgA-C3 immune complexes, within which antigenic moiety 
remains elusive [38]. IgAN has conventionally been subdivided into primary and secondary 
IgA nephropathy, depending upon whether there is absence or presence of recognizable 
systemic conditions, respectively. These systemic diseases refer to Henoch-Schonlein 
purpura, dermatitis herpetiformis, liver cirrhosis, chronic hepatitis, coeliac disease, 
ankylosing spondylitis, rheumatoid arthritis, Reiter’s syndrome, human immunodeficiency 
virus infection, mycosis fungoides and lung cancer. 
     Renal biopsy is necessary to establish the diagnosis of IgAN and also useful in 
prognostic information it may provide for the management of patient, clinical trials, and 
for assessing renal survival. 
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Histopathology of IgA Nephropathy : 
       There have been many proposed classifications of renal lesions, but none of these is 
widely adopted. The separation of renal lesions into active and chronic is somewhat 
arbitrary, in that the pathogenesis of these lesions is poorly understood. 
  
Acute Renal Lesions in IgA Nephropathy : 
       Mesangial hypercellularity  is diagnosed when the mesangial cells exceed three per 
segmental area to as much as ten or 20 mesangial cells. This lesion is common, with 
characteristic focal and segmental distribution, particularly in early disease. These may be 
accompanied by expansion of mesangial matrix or sclerosis. Mesangial hypercellularity is 
not correlated with disease progression or renal survival [39]. 
       Necrotizing lesion can be defined when any three of the following features are 
identified in glomeruli - disruption of capillary wall, mesangiolysis, leucocytic infiltration, 
nuclear fragments, fibrinous deposits or cellular crescents. It is seen in about 10% of 
patients with IgAN and up to 50% in the nephritis of Henoch-Schonlein purpura. While this 
lesion may not affect actuarial renal survival, immunosuppression is beneficial to prevent 
flares and progression to end-stage renal failure in some of the patients [40]. 
       Epithelial hypercellularity forming three or more solid layers constitute a cellular 
crescent. Some cases may respond to cytotoxic drugs and plasma exchange [41]. 
      In contrast to lupus nephritis, global endocapillary hypercellularity with or without 
leucocytic infiltration, and interstitial inflammatory cells infiltrates unrelated to tubulo-
 17
interstitial fibrosis are all uncommon. When present, these consist generally of modest 
focal and segmental lesions in IgAN. These glomerular lesions have not been correlated 
with disease progression or renal survival. 
 
Chronic Renal Lesions in IgA Nephropathy :  
         Glomerular sclerosis refers to accumulation of mesangial or basement membrane 
matrix. Its pathogenesis is incompletely understood, but inflammatory mediators such as 
TGF-β, PAI-1, and PDGFs play an important role in their development and their 
progression [42]. The clinical correlation between extent of glomerular sclerosis and loss of 
renal function supports the notion that sclerosing process is cumulative and parallels the 
progressive decrease in functional nephrons. 
          Tubular atrophy and interstitial fibrosis - In part they result from glomerular 
sclerosis and are regarded as secondary to the primary glomerular injury. There is no 
evidence of an immune mediated tubular insult as in lupus nephritis, however activated 
inflammatory mediators and inflammatory cells induced by chronic proteinuria are 
contributory [43]. In most biopsies however, the extent of tubular atrophy and interstitial 
fibrosis matches that of glomerulosclerosis, and correlated by semi-quantitative analysis 
[44]. Three patterns of chronic tubulo-interstitial lesions can be recognized in IgAN. Most 
commonly, tubular atrophy and interstitial fibrosis appear diffuse and parallel the extent of 
glomerular sclerosis. The second pattern of tubulo-interstitial scarring refers to the so-
called “striped fibrosis” distribution, which consists of groups of atrophic tubules and 
advanced glomerular sclerosis, alternating with groups of intact nephrons. It results from 
hypertensive hyaline arteriosclerosis. The third pattern is uncommon, and may be 
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recognized when tubular injury appears more pronounced than the extent of glomerular 
sclerosis, this raises the possibility of a superimposed drug-induced interstitial nephritis. 
          Hyaline arteriosclerosis  is identified in at least a third of the patients with IgAN at 
the time of biopsy, and is attributed to hypertension. 
 
 
Immunofluorescence Examination of IgA Nephropathy :  
     Mesangial deposition of predominant IgA-C3 immune complexes defines the 
disease[45] and consists mostly of polymeric IgA1 with the absence of secretory 
component and presence of J chain, regarded as the result of abnormal glycosylation of the 
IgA1 molecule [46]. Peripheral capillary loop deposits may or may not be found. 
 
 
Ultrastructural Examination of IgA Nephropathy : 
      In a majority of patients with IgAN, the findings of electron microscopy do not add to 
the diagnosis. The salient feature consists of mesangial electron dense deposits (EDDs), 
which are per se not diagnostic, unless done using immuno-electron microscopy labeling 
with anti-human IgA and C3 reagents [47]. A particular globular distribution of mesangial 
or paramesangial EDDs protruding into the urinary space is common in IgAN, but rarely 
seen in other glomerulonephritis. Truly isolated subendothelial or subepithelial EDDs are 
observed in 10% to 20% of the cases in the literature [48]. 
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      Two or more primary glomerular diseases may co-exist or be overlapping, requiring 
electron microscopy for diagnosis. Co existent minimal change nephropathy, membranous 
nephropathy, diabetic nephropathy and thin membrane nephropathy are recognized. 
 
 
Tubulointerstitial Injury in IgA Nephropathy : 
       In IgA nephropathy, several studies have shown that the degree of tubular atrophy and 
interstitial fibrosis correlate better with deterioration of renal function than the extent of 
glomerular injury. In a study of 194 patients with a mean follow-up of ten years, tubular 
grade 2 defined as  ≥ 25% but  < 50% tubular damage (relative risk: 5.5) and grade 
3 defined as > 50% tubular damage (relative risk: 28.8) were the best factors to predict 
chronic renal failure in multivariate analysis [49]. 
       To et al. examined separately the degree of glomerulosclerosis, tubulointerstitial  
damage, and hyaline arteriosclerosis in 126 renal biopsies of IgA nephropathy. In this 
study, global glomerulosclerosis represented the only independent prognostic factor for 
renal survival. Both glomerulosclerosis and  tubulointerstitial damage, however, were 
significantly correlated with the degree of proteinuria, hypertension and serum cre- 
atinine level [39] . 
        More recently, Myllymaki et al.analyzed 204 renal biopsies of IgA nephropathy and 
concluded from a multivariate analysis that interstitial fibrosis and tubulointerstitial 
inflammation were independently associated with progressive disease[50]. 
 20
         In the evidence-based Oxford classification 2008 for IgA nephropathy, tubular 
atrophy/interstitial fibrosis was significantly associated with renal outcome independently 
of glomerular filtration rate, proteinuria, and blood pressure at presentation. 
         Altogether these independent clinicopathological studies reveal that the degree of 
tubulointerstitial damage correlates with deterioration of renal function in IgA nephropathy. 
         The principal mechanisms implicated in the progression of tubulointerstitial injury in 
IgA nephropathy are –  
 
  1. Glomerulo-Tubular Communication : 
      In recent years, glomerulotubular crosstalk has been proposed as one of the 
 mechanisms involved [43]. Upon deposition of IgA, mesangial cells start to proliferate 
and release cytokines/chemokines, among which TNF-α and IL-6. These inflammatory 
mediators are filtered by damaged glomeruli and stimulate downstream tubular epithelial 
cells(TECs), which subsequently produce proinflammatory mediators including IL-1, 
TNF-α, MIF, IL-8,MCP-1, RANTES, and sICAM-1 [51]. 
 
2. Proteinuria : 
      Proteinuria leads to activation of the nuclear NF-κB transcription factor in TECs that, 
in turn, induces the up-regulation of pro-inflammatory cytokines/chemokines including 
MCP-1, RANTES, and osteopontin but also of the profibrogenic cytokine TGF-β [52]. 
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3. Downstream interstitial fibrosis due to reduced blood supply because of 
glomerulosclerosis . 
 
4.Misdirected filtration into the interstitium from the synechiae of 
glomerulosclerotic segments. 
 
5. Leukocytes : 
      Chemokines play pivotal roles in the recruitment of inflammatory cells into the 
kidney. The chemokine receptors CXCR3 and CCR5 are expressed on activated T cells. 
Interstitial CXCR3, as well as CCR5-positive T cells may play a role in the progression 
of renal diseases [53,54] . 
      PDGF is a potent chemo-attractant for macrophages. In addition,it causes the release 
of other cytokines among which TGF-β is predominant. Interstitial PDGFR-β is 
significantly increased in IgA nephropathy and associated with monocyte/macrophage 
infiltration [55]. 
     The secretion of cytokines by TECs not only leads to up-regulation of adhesion 
molecules including ICAM-1 and CD44 but also of MHC class II and the co-stimulatory 
signals CD80 and CD86,which support infiltration and activation of inflammatory 
cells.In a study comprising 33 cases of IgA nephropathy, CD80/CD86 expression 
correlated with renal function at the time of renal biopsy and with monocyte/macrophage 
infiltration. These data support the hypothesis that TECs in IgA nephropathy may act as 
antigen presenting cells and activate T cells [56]. 
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      In contrast, little has been published about B-cell infiltration and IgA nephropathy. 
Heller et al. characterized B-cell infiltrates and the factors involved in B-cell recruitment 
in 18 cases of IgA nephropathy. They concluded that CD20-positive B cells form a 
prominent part of the interstitial inflammatory infiltrate and that B-cell infiltrates are 
associated with increased local expression of the chemokine CXCL13 and the 
corresponding receptor CXCR5 on B cells. However, no correlation could be established 
between B cell infiltration and the Haas classification of IgA nephropathy [57]. 
 
6. Growth Factors  
       Hepatocyte growth factor (HGF) has recently emerged as a potent antifibrotic and 
reno-protective factor that counteracts the pro-fibrotic actions of TGF-β [58]. This may 
represent an endogenous mechanism of repair. 
       The expression of TGF-β is increased in tubules and tubulointerstitial areas in IgA 
nephropathy and correlates significantly with the severity of histological damage [59]. 
TGF-β has also been shown to induce the activation of the transcription factor c-Jun in 
TECs that in turn regulates the expression of genes involved in proliferation and 
inflammation [60]. 
       Progression of renal disease correlates with rarefaction of the peritubular capillary 
network which results from an increase in the expression of the anti-angiogenic factor 
thrombospondin-1 (TSP-1) and decrease of the pro-angiogenic factor vascular endothelial 
growth factor (VEGF) by tubular epithelial cells[61]. 
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7. Myofibroblast Influx  
        Accumulation of myofibroblasts in the interstitium is a key event in the development 
of fibrosis. These cells are characterized by the expression of  α-smooth muscle actin (α-
SMA) and fibroblastic-specific protein-1(FSP-1) [62]. In a series of 38 patients with IgA 
nephropathy, the intensity of the interstitial α-SMA staining correlated with renal 
functional outcome [63]. 
 
8. Matrix Metalloproteinases 
         Accumulation of extracellular matrix (ECM) results from an imbalance between 
synthesis by myofibroblasts and degradation by matrix metalloproteinases (MMP) [64]. 
Surprisingly, very few studies address the issue of MMP activity in IgA nephropathy. 
Brisk glomerular activity of MMP-9 and, to a lesser extent, MMP-2 has been reported in 
IgA nephropathy [65]. Furthermore, peripheral blood mononuclear cells(PBMCs) from 
patients with IgA nephropathy have been shown to express higher level of MMP-9 
mRNA than those from patients with other forms of glomerulonephritis or from healthy 
controls [66].Also, MMP-9 mRNA production by PBMCs correlated significantly with 
the severity of histopathologic grading for IgA according to Haas. 
        Although these data suggest that PBMC-derived MMP are of importance during 
disease progression in IgA nephropathy, solid data on MMP activity in the 
tubulointerstitial compartment in IgA nephropathy are currently lacking.MMP-9 activity 
can lead to destruction of the tubular basement membrane which in turn results in 
myofibroblastic transition of TECs via epithelial-mesenchymal transition. 
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9. The Renin-Angiotensin System 
       The Renin-Angiotensin system (RAS) has been shown to play a key role in the 
development of renal fibrosis. While several components of the RAS exert profibrotic 
activity, Angiotensin II (Ang II), produced by activated macrophages and fibroblasts has 
been shown to be the key hormone responsible for renal fibrosis [67]. Ang II induces 
expression of several cytokines/chemokines, including TGF-β, TNF-α, IL-6, MCP-1 and 
RANTES, through interaction with the Ang II receptors type 1 and 2 (ATR1 and ATR2) 
[68]. 
    Furthermore, Ang II influences renal tissue turnover by mediating TEC apoptosis (via 
interaction with ATR2) while at the same time mediating TEC proliferation (via 
ATR1)[69]. Pharmacologic blockade of the RAS effectively slows down the progression 
of interstitial fibrosis [70]. 
    In IgA nephropathy, the intrarenal RAS is activated.In a study of 20 renal biopsies 
from IgA nephropathy patients, mRNA levels of angiotensinogen, renin, ACE and AT1R 
and AT2R were significantly enhanced in both microdissected glomerular and 
tubulointerstitial tissue samples [71]. 
 
10. CD44  
      The shortest form of CD44, CD44 standard (CD44s), is able to bind hyaluronan and 
osteopontin, two major components of the extracellular matrix. CD44 comprises a family 
of type I transmembrane glycoproteins with a wide tissue distribution that are involved in 
cell-cell and cell-matrix interactions [72]. Using murine models of renal diseases, it has 
been shown that CD44 plays a crucial role in the cascade of renal inflammation, tubular 
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atrophy, rarefaction of the peritubular capillary network and ultimately fibrosis [73]. 
Under normal conditions, CD44 is undetectable in the kidney except in passenger 
leukocytes. In IgA nephropathy, a strong basolateral expression of CD44 was observed in 
damaged tubules as well as in the interstitium. CD44 expression paralleled the degree of 
tubular atrophy and interstitial fibrosis and correlated significantly with the degree of 
proteinuria[74]. 
 
Podocyte Pathology :  
     Podocytes are unique epithelial cells necessary for maintaining the selectivity and 
integrity of the glomerular filtration barrier. Podocytes have also been shown to fully 
express most or all the elements of the renin-angiotensin system (RAS) [75]. In vitro 
studies of podocytes cultured with either supernatant from mesangial cells cultured with 
polymeric IgA isolated from patients with IgA nephropathy (IgAN) or recombinant 
tumor necrosis factor-α (TNF-α) reveal enhanced proinflammatory changes with 
increased synthesis of TNF-α and interleukin-6 (IL-6) [76]. 
     Necrosis and detachment of the podocytes from the glomerular basement membrane 
was observed in IgAN [77]. Complementing the histological findings of podocytopenia, 
patients with IgAN had increased urinary excretion of podocytes[78]. Treatment with 
angiotensin-converting enzyme inhibitor or angiotensin II receptor antagonist reduced the 
urinary excretion of podocyte in IgAN [79]. 
      Lai et al. examined the expression of two podocyte markers (nephrin and ezrin) in 
renal biopsy from patients with IgAN with mild histological grading. A reduction in 
nephrin and ezrin was clearly evident in these patients with mild IgAN. These markers 
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were examined as nephrin has a crucial role in the filtration barrier of the glomerular 
podocyte and ezrin is a glomerular epithelial cell marker of podocyte injury 
(podocytopathy) [80]. 
      Although IgA isolated from patients with IgAN exerted no apoptotic effect on 
podocytes,  in vitro studies revealed TNF-α released from glomerular mesangial cells 
after IgA deposition modulates the expression of Bcl-2 by podocyte through auto-
amplification of TNF-α [81]. There is an apoptotic effect of mesangial derived-TNF-α on 
podocytes in chronic IgAN. 
 
Mechanisms of Podocyte Injury in IgAN :  
   It is well demonstrated that a glomerulo-tubular cross-talk involving TNF-α exists in 
IgAN  [51]. Lai  et al. hypothesized that a similar glomerulo-podocytic cross-talk existed 
in IgAN  [76]. Humoral factors/mediators from mesangial cells like TNF-α first activated 
the podocytes before reaching the tubulointerstitium either by glomerular filtration or by 
transportation via the post-glomerular capillaries. TNF-α receptor-1 (TNF-R1) and 
receptor-2 (TNF-R2) are constitutively present in normal podocytes. In vitro study 
suggests two functional roles played by the TNF-R1 in podocytes following stimulation 
by IgA-mesangial cell conditioned medium from patients with IgAN: IL-6 synthesis and 
apoptosis. Lai et al.suggests podocytes are in a chronic pro-inflammatory state in IgAN. 
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Clinicopathologic Findings :  
 
Pathogenesis –  
    IgAN arises as a consequence of circulating IgA1-containing immune complexes 
binding to mesangial cells. The IgA1 in these complexes has a reduced content of 
galactose in hinge-region O-glycans to constitute a neoantigen that is recognized by 
circulating IgG or IgA1 [82]. The galactose deficiency accentuates binding of the IgA1 to 
mesangial cells. The resulting stimulation of mesangial cells leads not only to their 
proliferation as the light-microscopic hallmark of this renal disease, but also to synthesis 
of extracellular matrix and secretion of a host of cytokines/chemokines that may 
culminate in inflammation and scarring in the glomerular and tubulointerstitial 
compartments [83]. 
     As a result of the glomerular damage, the filtration barrier is compromised and red 
blood cells and proteins enter the urinary space. These components may mediate 
additional injury, especially through interactions with podocytes and proximal tubular 
cells. Proximal tubular epithelial cells may also undergo transformation to mesenchymal 
cells and secrete extracellular matrix proteins to initiate interstitial scarring. Subsequent 
stimulation of fibroblasts/myofibroblasts in the renal interstitium augments the fibrosis 
[84]. 
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Prognostic Factors : 
   Demographic Characteristics : 
      Among demographic features, male gender [85], and older age [14] and perhaps 
obesity[86] portend a worse long-term outcome for patients with IgAN. 
 
 Clinical Features : 
       Patients with at least one episode of synpharyngitic hematuria fared better than those 
who had never experienced this degree of glomerular bleeding [87]. There is nearly 
universal agreement that hypertensive patients fare less well than normotensive patients. 
The National Kidney Foundation in the United States recommends blood pressure 
<130/80 mm Hg for patients excreting < 200 mg protein per g creatinine per day and a 
lower target for patients excreting > 1000 mg protein per g creatinine per day. 
 
Laboratory Findings : 
          Even mildly impaired eGFR (45–60 ml/min/1.73 m2) at the time of diagnostic 
biopsy have outcomes worse than those with normal clearance function. 
          Proteinuria has generally correlated with prognosis, although the threshold for a 
deleterious effect has been less clear. Analyses found a continuous-variable effect, with 
an adverse influence starting at 500 mg/day. More importantly, rather than one 
measurement at the time of biopsy, change in proteinuria over several years is a better 
gauge [88]. A study in Toronto showed that the cut-off was a time averaged value of 1 
g/day, calculated as the average of six-month-interval means after diagnosis [89]. In one 
study, patients with microalbuminuria at biopsy were more likely to develop proteinuria, 
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hypertension, and renal insufficiency (eGFR < 60 ml/min/m2) 7.5 years later than were 
patients with normal albuminuria at biopsy [90]. 
        Other laboratory features associated with worse outcome include hyperlipidemia and 
hyperuricemia. 
 
Light-Microscopy Histology :  
       A low number of podocytes per glomerulus has been associated with worse 
proteinuria and a decrement in renal clearance function [91]. Other glomerular features 
signifying an unfavorable outcome include endothelial cellular proliferation, focal 
necrosis, focal segmental scars, extracapillary cellular proliferation (a crescent if involved 
area exceeds 10% of the circumference of Bowman’s capsule) and global sclerosis. 
       Another vascular feature associated with poor prognosis is thrombotic 
microangiopathy [92]. 
        Degree of interstitial damage is a better prognostic indicator than degree of injury 
within glomeruli [90]. Enumeration of fibroblasts after staining for 
fibroblastic-specific protein 1 (FSP1) has been correlated with extent of 
glomerulosclerosis and interstitial fibrosis. Other poor prognostic factors are intensity of 
staining for CD3+ lymphocytes, increased numbers of  Mac387+ 
monocytes/macrophages and 27E10+ (activated) macrophages, intensity of interstitial 
staining for CD44, increased interstitial expression of iNOS, granule membrane protein 
of 17 kDa (GMP-17)-positive T-lymphocytes within renal tubules and B-lymphocytes in 
the interstitium. 
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Beyond Light Microscopy :  
     IgG in the mesangial immune deposits, immune deposits in the capillary loops on 
electron microscopy are other poor prognostic factors. 
 
Potential New Prognostic Markers :  
      A high serum IgA/C3 ratio was correlated with worse histological lesions in non-
nephrotic patients and a ratio above 4.5 indicated a worse renal survival [93]. 
      Urinary IL-6 or the IL-6/epidermal growth factor ratio and greater amounts of IL-8, 
TGF-β, and transforming growth factor-α1 have been proposed as markers of poor 
prognosis. 
 
Genetic Markers :  
      Genes with polymorphisms associated with outcome include those encoding ACE-
DD , angiotensinogen and CC-chemokine receptor  in whites, and plasminogen activator 
inhibitor-1,selectin, FcγRIIa and FcγRIIIa, angiotensinogen, peroxisome proliferator -
activated receptor γ, T-cell receptor, transforming growth factor-β1, and paraoxonase. 
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Pathology based grading systems :  
 
Classification 
Author/Year 
 
      Grade 1 
   
      Grade 2 
    
       Grade 3 
   
       Grade 4 
   
      Grade 5 
 
 
SPNSG/19821 
Minimal glomerular 
changes 
Mesangial 
proliferation only 
Any focal or 
sclerotic lesion 
  
 
 
Haas/19972 
Minimal or no 
mesangial 
hypercellularity ; 
without sclerosis or 
crescents  
Focal segmental 
glomerulosclerosis 
;minimal increase in 
mesangial 
hypercellularity; 
no crescents  
Focal proliferative 
changes , <50% 
glomeruli are 
hypercellular 
Diffuse proliferative, 
> 50% glomeruli are 
hypercellular  
Advanced sclerotic 
changes, ≥40% 
glomeruli are 
globally sclerotic 
and/or ≥40% tubular 
atrophy or loss of 
cortex 
 
 
 
To/20003 
Mean glomerular 
sclerosis 
<25%.Tubular 
atrophy and 
interstitial fibrosis 
<5% 
Mean glomerular 
sclerosis 25%-49%. 
Tubular atrophy and 
interstitial fibrosis 
5%-49% 
Mean glomerular 
sclerosis ≥50%. 
Tubular atrophy and 
interstitial fibrosis 
≥50%. 
  
 
 
Lee/20054 
Normal or focal 
mesangial cellular 
proliferation 
Diffuse mesangial 
cellular proliferation, 
or <25% of 
glomeruli with 
crescents, 
segmental/global 
sclerosis 
25% to 49% of 
glomeruli with 
crescents, 
segmental/global 
sclerosis 
50% to 75% of 
glomeruli with 
crescents, 
segmental/global 
sclerosis 
>75% of glomeruli 
with crescents, 
segmental/global 
sclerosis 
 
 
 
 
Wakai/20065 
Slight mesangial cell 
proliferation and 
increased matrix 
Slight mesangial cell 
proliferation and 
increased matrix. 
Glomerulosclerosis, 
crescent formation or 
adhesion to 
Bowman’s capsule 
in < 10% of 
glomeruli. 
Moderate diffuse 
mesangial cell 
proliferation and 
increased matrix. 
Glomerulosclerosis, 
crescent formation or 
adhesion to 
Bowman’s capsule 
in 10% to 30% of 
glomeruli 
Severe diffuse 
mesangial cell 
proliferation and 
increased matrix. 
Glomerulosclerosis, 
crescent formation or 
adhesion to 
Bowman’s capsule 
in > 30% of 
glomeruli 
 
 
 
 
Manno/20076 
Normal glomeruli or 
slight increase in 
mesangial matrix 
and/or cellularity 
Moderate or diffuse 
mesangial 
proliferation and/or 
focal segmental 
sclerosis and/or 
endocapillary 
proliferative and/or 
cellular crescents in 
≤50% of glomeruli 
Cellular crescents in 
> 50% of glomeruli 
and/or global 
sclerosis and fibrous 
crescents involving > 
1/3 of glomeruli 
and/or diffuse 
segmental sclerosis. 
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Clinical Course of Primary IgA Nephropathy :  
       The definition of IgAN is still pathological and needs a renal biopsy for diagnosis. 
The agreed definition is the deposition of at least 1+ (on a semi-quantitative scale: 0 = no 
deposits; +/−= traces; 1+, 2+ and 3+) immunoglobulin A (IgA) in the mesangial area of 
glomeruli. The characteristics of these IgA deposits are the followings: granular, coarse 
with the “en mottes” aspect, predominantly mesangial, dominant or codominant with 
other immunoglobulins such as IgG and/or IgM, associated with C3 deposits at the same 
location, and global and diffuse in contrast to the light microscopy lesions which are 
often segmental and focal. Once the diagnosis of IgAN is made, the clinician has to 
differentiate the primary form, also called Berger’s disease, which represents 
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about 80% of all cases from the secondary forms. 
       Comparisons between males and females showed that females had significantly less 
proteinuria, lower GOS, and lower serum IgA level . In general at time of diagnosis, the 
clinical presentation was less severe in females. 
      The natural history of primary IgAN is both clinical and pathological progression 
towards chronic renal failure (CRF) and end-stage renal failure (ESRF) [94 ,95 ]. In the 
literature, the cumulative incidence at 20 years of ESRF/dialysis varies from 
10% to 40% depending on the policy of renal biopsy. 
 
IgA Molecule in IgA Nephropathy :  
    Deposited IgA is predominantly polymeric IgA (pIgA) of the IgA1 subclass and has 
been shown to be differentially glycosylated. Moreover, vaccination studies have 
demonstrated alterations in mucosal immunity, whereas in many patients mucosal 
infections are associated with episodes of macroscopic hematuria. 
     Plasma IgA1 are elevated in about half of the IgAN patients [96]. The elevated IgA 
concentration seems to be the result of higher production of IgA by plasma cells in the 
bone marrow[97]. Next to the higher concentrations of IgA1, qualitative changes of IgA 
in IgAN patients have been described. IgA of IgAN patients contains a reduced 
galactosylation of the O-linked glycans in the hinge region [98]. 
     Patients with IgAN have a hampered primary mucosal IgA immune response. As a 
result of this mucosal hyporesponse, the clearance of antigens might be less effective 
leading to a prolonged antigen exposition,which might eventually lead to higher levels of 
memory and higher IgA serum titers . The fact that other diseases with high serum 
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IgA concentrations, like multiple myeloma or HIV, are not associated with renal IgA 
depositions supports the idea that the higher IgA1 concentrations are not the only cause 
of mesangial IgA deposition in IgAN. 
      Dendritic cells (DC) might be less effective in inducing IgA production by naïve B 
cells. DC derived from IgAN patients showed a reduced capacity to induce IgA 
production in the presence of IL-10 [99]. However, so far it not clear which factors are 
responsible for the disturbed DC function in IgAN patients. 
     Galactose deficiency of IgA1 appears to be a key pathogenetic factor contributing to 
the development of the disease. Circulating complexes in IgA nephropathy contain IgA1 
with galactose-deficient hinge-region O-linked glycans [82]. Notably, galactose-deficient 
IgA1 is the predominant glycosylation variant of IgA1 in the mesangium[100]. Cells 
from patients with IgA nephropathy had low expression and activity of the corresponding 
galactosyltransferase and high expression and activity of sialyltransferase. Consequently, 
the O-glycans on the secreted IgA1 are galactose deficient with high proportion of 
GalNAc being sialylated [101]. In view of the fact that sialylation was shown to prevent 
galactosylation of GalNAc, it is quite possible that “premature” sialylation helps to 
increase the levels of galactose-deficient O-glycans in IgAN. 
        After alteration of the glycosylation of the IgA1, neoepitopes represented by IgA1 
glycans or hinge-region glycopeptides are exposed and recognized by 
naturally-occurring antibodies with anti-glycan or anti-glycopeptide specificities[102]. 
Clones of EBV transformed peripheral blood lymphocytes from IgAN patients in culture 
secrete IgG antibodies specific for galactose-deficient IgA1. Thus, the presence of 
glycan-specific anti-IgA1 antibodies promotes formation of immune complexes.The 
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resultant IgA1 complexes are relatively large. Because of their size, they are not 
efficiently cleared from the circulation and thus tend to deposit in the renal mesangium. 
     Galactose-deficient IgA1 is retained in the circulation for long periods of time. 
Galactose deficiency in itself should not hinder disposal of IgA1 molecules because the 
asialoglycoprotein receptor recognizes terminal GalNAc as well as galactose.However, if 
the GalNAc is linked to sialic acid or is covered by an antibody, it cannot be recognized 
by the hepatic asialoglycoprotein receptor and is not catabolized [103]. 
 
       Immunopathogenesis of IgAN is considered to occur in three phases –  
1. In the early primary phase, B cells produce polymeric IgA (pIgA) in response to 
variety of antigens that initiates glomerular IgA immune deposit formation. 
2. In the secondary phase, continuous activation of the mesangial cells, the complement 
system and the innate immune system by persistent glomerular pIgA immune deposits 
attract macrophages that produce inflammatory mediators leading to glomerulosclerosis. 
3. In the tertiary phase, interstitial infiltration by T cells cause tubular injury and sets in 
motion irreversible interstitial fibrosis leading to end stage renal failure in 20%–40% of 
the affected patients. 
 
Antigen-Dependent Mechanism of IgA Nephropathy : 
       Since IgA is an important immunoglobulin in defense mechanisms against 
exogenous antigens in the mucosal system, the antigens might be located in the mucosal 
membranes of patients with IgA nephropathy. However, it is not still known whether 
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antigens are exogenous and/or endogenous in patients with IgA nephropathy. It is 
speculated that there are many kinds of antigens, i.e. food, virus, bacteria and/or  
fungus, in patients with IgA nephropathy as follows: (1) dietary antigens,(2) respiratory 
antigens, (3) intestinal antigens, (4) biliary antigens, and(5) dermal antigens. These 
antigens might form antigen-antibody dependent immune complexes. 
      Food components such as bovine albumin, ovalbumin , lactoglobulin , gliadin have 
been implicated. 
      IgA nephropathy is frequently preceded by episodes of upper respiratory tract 
infection that is presumed to have some viral etiology [104]. Virus-like particles and/or 
microtubular structures were occasionally observed in the glomerular mesangial areas by 
electron microscopy. 
Slight deposition of adenovirus, herpes simplex, varicella zoster or parainfluenza 3 virus 
was observed by immunofluorescence [106], the contributory role of which is debated. 
        IgA nephropathy has been described as a complication of infections with Yersinia 
enterocolitica, Campylobactor jejuni, and Mycoplasma pneumoniae. Suzuki  et al. 
observed glomerular deposition of  Hemophilus parainfluenzae antigens by 
immunofluorescence and the presence of IgA antibody  against H. parainfluenzae in sera 
by enzyme-linked immunosorbent assay (ELISA) in patients with IgA nephropathy [16]. 
 
Complement Activation :  
      In addition to mesangial IgA deposits, biopsies of IgAN are commonly associated 
with the deposition of complement components, most notably C3, the membrane attack 
complex (C5b-9), and properdin, suggesting the participation of alternate pathway 
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complement in disease pathogenesis [108]. Local complement production by various 
intrinsic renal cells and infiltrating cells may contribute to tissue injury in IgAN [109]. 
      Moreover, proteinuria but not serum creatinine, at the time of renal biopsy correlated 
with C3 mRNA expression. This last phenomenon may be attributed to the finding that 
apical proteins stimulated basolateral C3 synthesis by cultured human proximal tubular 
epithelial cells, in which transferrin and apotransferrin stimulated C3 biosynthesis more 
intensely. Locally secreted C3 may further activate tubular cells via the C3a receptor to 
enhance renal injury [110]. Evidence is accumulating that complement activation via 
MBL and the lectin pathway is also associated with disease progression in IgAN [111]. 
More recent data suggest that IgA was co-deposited with MBL in about 25% of patients 
and that MBL deposition showed more severe renal disease as compared with MBL-
negative cases, suggesting an important role for MBL in disease progression [112]. 
 
Corticosteroids :  
    For decades, these agents have been used with the concept of a non-specific but very 
potent antiinflammatory effect. 
       In 1986 Kobayashi et al. first reported their experience coming from a prospective, 
non-randomized study of 14 IgAN patients with proteinuria between 1.0 and 2.0 g/day 
who received an initial dose of 40 mg/day of prednisolone, followed by gradual reduction 
of the dose over an average period of about 19 months. Compared to the 29 control 
subjects, patients treated with steroids had considerable reduction in proteinuria and 
better preserved renal function; those with creatinine clearance higher than 70 ml/min 
seemed to benefit more from therapy [113]. 
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       Encouraging results were also obtained in 13 children who were treated with 
alternate day prednisone 60 mg/m2 for three months,reduced to 30 mg/m2 by one year 
and 15 mg/m2 by two years. In comparison with a historical group, Waldo  et al. showed 
a significant improvement in urine analysis (both proteinuria and hematuria) and a 
preserved normal GFR. Follow-up biopsy after two years of treatment revealed a 
significant fall in the activity score (from 5.2 to 4.3), without any significant increase in 
the chronicity score [114]. 
         Conversely, first reports coming from small, randomized clinical trials were mostly 
negative. Lai  et al. found no benefit of prednisone (1 mg/kg/day for two months and a 
tapered dosage for another two months) in a controlled trial involving 34 patients with 
nephritic syndrome. However, the length of treatment (only four months) was 
perhaps not long enough [115].  
        Julian et al. made a multicenter prospective trial in IgAN patients with proteinuria 
greater than 2 g/day by comparing symptomatic therapy with alternate-day prednisone 
(60 mg/day tapered by 10 mg every three months to 10 mg/day over 24 months). 
However, they published only preliminary data of a small set of patients not supporting a 
favorable effect of steroids (only a modest reduction in proteinuria was observed) [116]. 
However, the lack of effectiveness on renal function may be due to a too short follow-up 
(nearly two years). 
      In 1987 Pozzi etal started a large, multicenter, randomized,open-label, controlled trial 
in order to evaluate the effects of corticosteroids in 86 adult biopsy-proven IgAN patients 
with normal renal function (serum creatinine  ≤1.5 mg/dl) and moderate proteinuria (1–
3.5 g/day). The patients were randomly assigned to receive either supportive therapy or 
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six-months’ steroid treatment (methylprednisolone 1 g intravenously for three 
consecutive days at the beginning of months 1, 3 and 5, plus oral prednisone 0.5 mg/kg 
every other day for six months). Baseline characteristics were comparable in the two 
groups. After five years of follow-up, renal survival was significantly better in the steroid 
treated patient group than in the control group for both the primary endpoints of 50% and 
100% increase from baseline plasma creatinine levels (respectively of 17% and 21%; log-
rank test p < 0.048 and p < 0.005). Evaluation of renal survival after ten years of follow- 
up confirmed that outcomes in the steroid-treated group were better than those in the 
control group (97% vs. 53%, p = 0.0003). Mean urinary protein excretion also 
significantly decreased in the steroid group (from 1.93 ± 0.45 g/day at baseline to 0.78 ± 
0.41 g/day at one year), and this decrease persisted throughout the follow-up,whereas 
proteinuria remained unchanged in the control group .It is likely that treatment with ACE 
inhibitors or ARBs did not affect the findings, since a similar percentage of patients in 
both groups received these agents. Interestingly, glucocorticoids were effective in 
every histological class. This suggests that the main indication to steroid treatment in 
patients with IgAN should be proteinuria level and not indexes of activity and/or 
chronicity at renal biopsy examination. None of the patients in the steroid group 
experienced any major side effects [117]. 
         More recently, in an open-label study, Katafuchi et al. randomized 90 IgAN 
patients with normal renal function to steroids (oral prednisolone 20 mg/day for one 
month followed by 15 mg/day for one month,10mg/day for one month, 7.5 mg/day for 
three months and 5 mg/day for 18 months) plus dipyridamole (150 or 300 mg/day) or 
dipyridamole alone at the same dose. Steroids significantly reduced proteinuria, but 
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were ineffective on renal survival. However, the event rate was very low (only three 
patients in each group progressed to end-stage renal disease during follow-up) and the 
study was severely underpowdered to show any effect on end-stage renal disease [118]. 
     No controlled, randomized studies have yet been conducted comparing intravenous 
pulse with oral steroid for IgAN. 
      There are few studies evaluating the effect of glucocorticoids on histological lesions. 
Yoshikawa et al.studied 78 children with IgAN and normal renal function, 40 of whom 
received prednisolone, azathioprine, heparin/warfarin and dipyridamole for two years, 
and 38 heparin/warfarin and dipyridamole alone. Clinical and pathological data before 
treatment were similar in the two groups. In the second biopsy, performed after treatment, 
the mean percentage of glomeruli showing segmental or global sclerosis was unchanged 
in patients treated with glucocorticoid and azathioprine, but increased from 3.9% to 
16.4% in patients who did not receive glucocorticoids [119]. 
        There are few clinical studies testing steroid therapy in IgAN patients with advanced 
disease. Tamura et al. studied retrospectively 60 IgAN patients with creatinine clearance 
below 70 ml/min at the time of renal biopsy (on average 58 ml/min), 20 of whom 
received steroids. The mean follow-up period was about 4.5 years. After one year, 
proteinuria decreased in the steroid group (from 2.33 to 1.02 g/day), but remained 
unchanged in the non-steroid group (from 1.39 to 1.28 g/day). Interpretation of results is 
slightly biased by the fact that before treatment, proteinuria was higher in patients 
receiving steroids (2.33 vs. 1.39 g/day in the control group). Even if serum creatinine was 
unchanged after one year in the two groups, at the final observation patients not treated 
with steroids had higher creatinine values compared to those receiving steroids 
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(2.51 vs. 1.79 mg/dl, respectively) [120]. 
 
Renin-Angiotensin Blockade :  
      In recent years, two prospective RCTs [123,124] proved that in proteinuric IgAN with 
rather good glomerular filtration rate, a significant effect of ACEi not only in reducing 
proteinuria but also in preserving renal function, and another RCT[126] proved that ARB 
decreases proteinuria and slows renal deterioration after adjustment for blood pressure 
control. The additional benefit of a combination therapy has never been adequately 
addressed in IgAN by properly designed RCT, and only short-term studies or RCT sub- 
analysis are available, which suggest a possible superior effect of the combination 
therapy in reducing proteinuria and possibly renal disease progression. 
 
Treatment of IgAN with ACEi :  
       A more recent prospective study pointed out a significant stabilization of GFR in 
IgAN only in the intensive treatment group, when BP was lowered to <130/70 mmHg 
(often using multidrug combinations), while patients with BP > 135/75 mmHg 
failed to be protected against functional decline [121]. 
       Dillon in 2001 performed a meta-analysis of 237 IgAN patients treated with ACEi 
and enrolled in three short-term crossover trials, one prospective RCT and three 
retrospective studies, and concluded that the effect on proteinuria was clear, while the 
renoprotective effect remained unproved [122]. 
       In 2003, a RCT of ACEi in IgAN was published by Praga et al. The trial was not 
placebo-controlled, and enrolled 44 subjects mainly of young age (< 40 years old) from 
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one single center with wide range of proteinuria (from 0.5 to 5 g/day) and various degrees 
of renal function impairment. Patients randomly assigned to enalapril or control group 
had similar baseline characteristics of GFR, proteinuria and BP. Enalapril was given at a 
starting dose of 5 mg/day and titrated to achieve and maintain a target BP of ≤ 140/90 
mmHg until a maximal dose of 40 mg/day.After a mean follow-up of 75 months, the 
proportion of patients developing the primary end point (50% increase of baseline plasma 
creatinine) was significantly lower in ACEi group than in the control group (12% versus 
57%, respectively). After four years of follow-up, renal survival was 100% in treated 
patients versus 70% in controls and this trend worsened after eight years when the renal 
survival decreased to 55% in placebo, versus 92% in treated subjects. Proteinuria 
significantly decreased in the treated group from 2 ± 1.3 g/day (0.5–5.3) to 0.9 ± 1.3 
g/day (0.5–5.3) ( p < 0.001) while no significant changes where observed in the control 
group [123]. 
        IgACE was the first placebo-controlled RCT designed to investigate the effects of 
ACEi in young IgAN patients (aged less than 35 years), with moderate proteinuria (> 1 
and < 3.5 g/day/1.73 m2 ) and GFR >50 ml/min/1.73 m2 . Sixty-six patients, meanly 20 
years old (range 9–35), were randomized to receive benazepril 0.2 mg/kg/day or placebo, 
and were followed for a median of 38 months. The end point of progression of IgAN was 
defined as >30% decrease of baseline creatinine clearance (CrCl) and also as a composite 
end point of >30% decrease of baseline CrCl and/or worsening of proteinuria until ≥ 3.5 
g/day/1.73 m2 was considered. Secondary outcomes included proteinuria, partial 
(<0.5 g/day/1.73 m2 ) or total remission (<160 mg/day/1.73 m2 ) for more than six 
months. One single patient (3.1%) in the ACEi group and 14.7% in the placebo group 
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reached the end point of renal function decline. No patient on ACEi developed nephrotic 
syndrome, versus 20.6% on placebo group. The renal disease progression to the 
composite end point of renal function decline and worsening of proteinuria above 
the nephrotic range resulted significantly different between the two groups of ACEi 
treated patients and those assuming placebo( p = 0.035). In conclusion, angiotensin 
antagonism was successful in limiting progression of renal damage in young 
IgAN patients with proteinuria between 1 and 3.5 g/day. ROC analysis identified 
1 g/day/1.73 m2 at one year as a cut-off level of proteinuria protective over progression. 
In the IgACE trial, patients with time average proteinuria < 1 g/day/1.73 m2 had a 
favourable survival to 30% reduction of baseline CrCl (100% survival after 58 months of 
follow-up), while those with time-average proteinuria between 1 and 3 g/day/1.73 m2 
had 75% survival and those over 3 g/day/1.73 m2 a 65% survival (log rank: 
p = 0.01) [124]. 
 
Treatment of IgAN with ARB : 
       In a short term study of 12 weeks, ARB therapy (losartan 50 mg) resulted superior to 
the calcium channel blocker treatment (amlodipine 5 mg) in reducing proteinuria and 
TGF-β1 excretion, even though BP control was similar[125]. 
         The long-term effects of ARB therapy in proteinuric IgAN have been recently 
demonstrated by Li  et al.in a multicenter, placebo controlled RCT. They enrolled 109 
patients from Hong Kong with IgAN and proteinuria greater than 1 g/day and serum 
creatinine level lower than 2.8 mg/dl, or serum creatinine level of 1.4 to 2.8 mg/dl, 
regardless of degree of proteinuria. Patients were assigned to valsartan, 80 mg/d 
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(titrated up to 160 mg/d for BP control), or placebo for 104 weeks.Additional 
antihypertensive therapy was allowed to achieve a target BP of 140/90 mmHg. 
Proteinuria decreased significantly in the treatment group but did not change in the 
placebo group. With multiple linear regression models, ARB treatment resulted in a 33% 
decrease in proteinuria after adjusting for other confounding factors. There was a 
significant decrease in mean rate of GFR decline in the ARB group (−5.62 ± 6.79 
ml/min/year), compared with the placebo group (−6.98 ± 6.17 ml/min/year) throughout 
the study period after adjustment for average BP and proteinuria ( p = 0.014). This RCT 
demonstrated that ARB significantly decreases proteinuria and slows renal deteriora- 
tion in patients with IgAN after adjustment for confounding factors, notably BP [126]. 
 
Combination Therapy in Proteinuric IgAN : 
    In a short-term clinical investigation, doubling ACEi or ARB doses in 12 adults with 
IgAN did not improve the antiproteinuric effect.However, a higher effect was 
observed when the two drugs were co-administered and an additional reduction in 
proteinuria was obtained when combined therapy doses were doubled [127]. 
     In 31 patients with IgAN and mild proteinuria (from 0.3 to 0.7 g/day), GFR > 50 
ml/min and normal BP, the dual blockade of RAS given for six months was reported to 
induce remission of proteinuria in 63% of the cases versus 41% in ACEi and 36% in 
ARB monotherapies [128]. 
     In conclusion, the additional benefit of a combination therapy has never been 
adequately addressed in IgAN by properly designed RCT; only short-term studies suggest 
a possible superior effect of the combination therapy in reducing proteinuria. 
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Cyclophosphamide in Combination with Corticosteroid :  
        In 2002, Ballardie et al. published a randomized, controlled, single center study on 
38 patients with progressive loss of renal function. Patients, none of whom had crescentic 
glomerulonephritis, were randomized to prednisolone and low-dose cyclophosphamide 
followed by azathioprine or supportive therapy only. Renal survival in treated patients 
showed considerably better preservation of function at five years (72% compared with 
6% in controls). Proteinuria and erythrocyturia reduced from 12 and six months of 
treatment, respectively. No side effect was reported apart from marrow suppression in 
one subject and pulmonary tuberculosis in another. This study may be faulted, however 
for suboptimal blood pressure control and insufficient use of medications that block the 
angiotensin system, the unusually poor survival rate of the placebo group, and the small 
number of patients [129]. 
         Tumlin et al. conducted a prospective, uncontrolled, open-label trial of 12 patients 
with crescentic IgAN and clinically progressive disease. Treatment consisted of three 
doses of methylprednisolone at 15 mg/kg/day, followed by intravenous 
cyclophosphamide at 0.5 g/m2 /month for six months. Serum creatinine fell from 2.7 to 
1.5 mg/dl, and proteinuria decreased from 4 to 1.3 g/day after treatment, suggesting a 
beneficial role of cyclophosphamide in crescentic glomerulonephritis [130]. 
         Mitsuiki et al. retrospectively examined the outcome of 35 patients with 
histologically advanced IgAN, in whom 27 received prednisolone for two years and oral 
cyclophosphamide (50mg/day) for six months, and the remaining eight received 
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supportive treatment. Renal prognosis was significantly better in the treatment group 
[131]. 
       Overall, these studies suggest that combined cyclophosphamide/steroid therapy may 
benefit IgAN patients at very high risk of renal failure, namely those with a progressive 
decline in GFR and/or crescentic lesions before randomization. However, more definitive 
evidence involving patients in sufficient numbers is required before this treatment can be 
widely accepted. 
 
 
 
Cyclosporin :  
      Lai et al. conducted a randomized prospective single blind study of 19 patients with 
proteinuria  > 1.5 g/day. Patients who received cyclosporin had significant reduction of 
proteinuria, serum IgA, and increase of plasma albumin concentration compared with 
placebo. However, there was transient deterioration of renal function during treatment, 
despite within-range trough drug levels. The authors discouraged indiscriminate use of 
cyclosporin in IgAN due to nephrotoxicity [132]. 
 
Azathioprine :  
        Goumenos et al. performed a retrospective analysis of 74 IgAN patients followed 
for ten years, and found that long-term azathioprine combined with low-dose prednisone 
did not alter the clinical course compared to untreated controls. However, in a subgroup 
of patients with heavy proteinuria greater than 3 g/day and baseline serum creatinine 
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between 1.4–2.5mg/dl, this immunosuppressive regimen reduced the risk of doubling 
serum creatinine compared to controls (27% vs. 78%) and delayed progression to end-
stage renal failure (17% vs. 55%) [133]. 
        The Japanese Pediatric IgA Nephropathy Treatment Study Group randomized 78 
children with newly diagnosed early IgAN to receive either prednisolone, azathioprine, 
heparin-warfarin, and dipyridamole or the combination of heparin-warfarin, and 
dipyridamole only. After two years, there was significant reduction of proteinuria and 
serum IgA levels in the prednisolone/azathioprine group, while there was no difference in 
renal function between the two groups. The study was flawed by a lack of data on 
baseline proteinuria and creatinine clearance as well as blood pressure control in both 
groups [134]. 
 
Mycophenolate Mofetil :  
       To date, four randomized clinical trials have been published on the use of MMF in 
IgAN,which add more controversy than consensus. 
       The first randomized study, published in 2002 in the Chinese literature,was 
conducted in Beijing in which 62 Chinese patients with severe IgAN with Lee’s grade IV 
and V renal histology and urinary protein > 2.0 g/d received MMF or oral prednisone for 
at least 12 months. After 18 months’ follow up, the MMF group showed significant 
improvement in proteinuria and serum lipids than the prednisone group [135]. 
        In 2004 Maes  et al. described a prospective study in 34 Belgian patients with 
impaired renal function who were randomized to 2 g of MMF (n = 21) or placebo (n = 
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13) after instituting salt restriction and angiotensin-converting enzyme inhibitor therapy 
in all. They only included patients with histologic unfavorable criteria and arterial 
hypertension, and excluded those with mild histopathologic changes despite heavy 
proteinuria. After three years of follow-up evaluation, inulin clearances and proteinuria 
did not differ between the groups [136]. 
        In 2005 Tang  et al published a prospective study in 40 Chinese patients with IgAN 
and mild tubulointerstitial lesions who were randomized 1:1 to 1.5 (BW < 60 kg) or 2.0 
g/day MMF for six months or continuation of contemporaneous medication only after 
blockade of the renin-angiotensin system failed to reduce proteinuria to < 1 g/d. Twelve 
months after stopping MMF, the overall remission rate (proteinuria < 0.3 g/d or 50% of 
baseline) was significantly higher in MMF-treated patients whose proteinuria dropped to 
62% of baseline, whereas urine protein in control patients increased to 120% of baseline. 
Adverse events in the MMF group included anemia, urinary tract infections and cervical 
lymphadenitis. There were no adverse events in the control group [137]. 
      In late 2005, Frisch et al. published a randomized controlled trial in which 32 
predominantly Caucasoid North American patients with advanced IgAN (mean serum 
creatinine, 2.5mg/dl) were randomized to MMF or placebo. MMF was given for one year 
as a “salvage” therapy in 16 patients with advanced renal insufficiency. Notably, the 
presence of glomerulosclerosis or tubulointerstitial atrophy and fibrosis on renal 
biopsy was an inclusion criterion. The study was terminated prematurely after observing 
a trend towards worse outcome in the MMF group [138]. 
       Overall, MMF appears to be effective in reducing proteinuria in Chinese but not 
Caucasoid IgAN subjects. Therefore, ethnic differences may be one possible reason to 
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account for the differences observed in  these studies. Another possibility is the mild 
histologic grade in Tang’s  study versus the moderate-to-severe grades in the studies by 
Maes and Frisch.Further observation and studies are needed to provide more definitive 
answers on the efficacy of MMF in IgAN. 
 
Other Immunomodulatory Therapy :  
      Lai et al.had performed plasma exchanges for two patients with crescentic IgA in 
whom corticosteroid and immunosuppressive therapy failed to control the progression of 
the disease. In both cases, the rapid progression of renal failure was apparently halted. 
Nevertheless, the long-term benefit of plasma exchange in crescentic IgA nephropathy 
was unsatisfactory as the renal function continued to deteriorate in the following 12 
months despite an initial stabilization [139]. 
         Lou et al. showed in 60 patients randomized to leflunomide or fosinopril  that 
leflunomide effectively suppressed proteinuria, however this effect was not superior to 
that achieved by fosinopril [140]. 
         In a study that employed 41 historical pediatric controls who received prednisolone, 
warfarin, and dipyridamole therapy before 1989, the addition of mizoribine in 20 subjects 
after 1990 appeared to be more effective in ameliorating proteinuria and histological 
severity on repeat biopsy at two years [141]. 
        Intravenous immunoglobulins, given monthly at a dose of 2 g/kg body weight for six 
months to eight patients with progressive IgAN, showed some benefit in prolonging renal 
survival by 3.5 years compared with eight patients with IgAN and similar level of renal 
function without receiving immunoglobulins [142]. 
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       Information of Rituximab (anti-CD20 antibody) for treatment of IgAN is lacking. 
 
Fish Oil : 
     The rationale for using fish oil supplements in patients with IgAN is based on 
experimental data suggesting that omega-3 polyunsaturated fatty acids may limit the 
immunologic renal injury in IgAN. These omega-3 fatty acids compete with arachidonic 
acid to produce trienoic eicosanoids which, in turn, may slow renal disease progression 
by reducing glomerular and interstitial inflammation, mesangial cell contractility, platelet 
aggregation, and vasoconstriction in response to renal injury [143]. 
       There have been six RCTs of fish oil (EPA and DHA) in IgAN. Two trials by the 
Mayo Nephrology Collaborative Group have demonstrated a renoprotective effect of fish 
oil in patients with persistent proteinuria[144,145]. 
      The first of these was an RCT of 106 patients with proteinuria  > 1 g/24 hours and 
impaired renal function at enrolment (60% also hypertensive) which found that those 
treated with fish oil had a slower rate of decline in GFR (but no improvement in 
proteinuria) at both two and five years[144].  
       A second RCT from the same center, included a further 73 patients with similar 
baseline characteristics, but used a historical control group (the authors argued it was 
inappropriate to include a control group in light of the benefits of fish oil in the initial 
study).Again, fish oil was associated with a slower rate of decline in GFR compared to 
the historical control group and this effect was independent of the dose of fish oil used 
[145]. 
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          These results have not been replicated in three other RCTs studying similar patient 
cohorts [146, 147, 148] and a meta-analysis (three trials, 175 patients) failed to detect a 
benefit of fish oils on renal outcome in IgAN [149]. 
      At present the available evidence does not yet give unequivocal support for the use of 
fish oil and a further confirmatory study of fish oil in IgAN would be of great value. 
There is no data in published clinical trials suggesting a synergistic or otherwise effect of 
co-administration of ACEI/ARB and fish oil. 
 
Tonsillectomy :  
      There are many experimental studies suggesting the involvement of a tonsillar 
autoimmune response in the pathogenesis of IgAN. Tonsillectomy is commonly 
performed in Japan for IgAN, especially combined with steroid pulse therapy, whereas it 
is only rarely performed in European countries and the USA. The main reason for this 
deep controversy is the lack of evidence from randomized controlled trials (RCTs). 
        Japanese studies show that tonsillectomy is beneficial only if done at an early stage 
of disease .The Okayama group in Japan followed 85 IgAN patients, 43 of whom had 
undergone tonsillectomy. They originally reported unfavorable results on renal survival 
at five years after the tonsillectomy. However, they subsequently recognized the 
favorable effects of tonsillectomy on renal survival rates after an observation period of 
ten years. The renal survival rate at ten years was 95.1% in the tonsillectomy group and 
73.3% in the non-tonsillectomy group [150]. 
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      Similarly, the Niigata group followed 118 patients with IgAN in which 48 underwent 
tonsillectomy, for 192.9 ± 74.8 months, and reported a favorable renal survival rate, as 
assessed by Kaplan-Meier analysis, in the tonsillectomy group [151]. 
 
Effect of Tonsillectomy plus Steroid Pulse Therapy : 
     Tonsillectomy and steroid pulse therapy have been demonstrated to be independent 
contributing factors for clinical remission. The likelihood of clinical remission (i.e. 
disappearance of both hematuria and proteinuria) with tonsillectomy  per se is less than 
50% even in patients with early-stage IgAN. On the other hand, a marked increase in the 
likelihood of clinical remission may be expected when tonsillectomy is combined with 
steroid pulse therapy in patients with early stage IgAN, which is approximately 80% of 
patients treated [152]. 
        While clinical remission is highly unlikely, slowing of disease progression by 
tonsillectomy plus steroid pulse therapy may be expected even in patients with advanced 
IgAN, if the serum creatinine level is under 2.0 mg/dl [153].  
         Unfortunately, there are no RCTs comparing steroid pulse therapy combined with 
tonsillectomy versus steroid pulse therapy alone. A multicenter prospective cohort study 
from Japan indicates a higher likelihood of clinical remission with steroid pulse therapy 
combined with tonsillectomy than with steroid pulse therapy alone, even in moder- 
ately advanced  IgAN patients[154]. 
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Indications of Tonsillectomy in Patients with IgAN :  
      The principle for tonsillectomy in IgAN patients is “the earlier the better.” The 
indications for tonsillectomy in patients with IgAN remain controversial. Some 
nephrologists contend that tonsillectomy should be restricted to IgAN patients suffering 
from recurrent episodes of tonsillitis or showing macroscopic hematuria after an episode 
of pharyngitis. Matsutani et al.,however demonstrated that the remission rates of both 
proteinuria and hematuria following tonsillectomy plus steroid pulse therapy were similar 
regardless of the history of recurrent tonsillitis, history of synpharyngitic gross hematuria, 
presence of pus plugs in the tonsillar lacunae, size of the tonsils, age or the results of the 
tonsillar provocation test [155]. Advancing histological score or clinical stage decreases 
the likelihood of clinical remission by tonsillectomy, regardless of whether or not it is 
combined with steroid therapy. 
        Therefore, the indications for tonsillectomy should be tentatively determined based 
mainly on the clinical or histological stage, with less importance attached to other 
parameters such as episodes of synpharyngitic gross hematuria, gross appearance of the 
tonsils or results of the tonsillar provocation test.  
 
Future Prospects for IgA Nephropathy : 
 
Diagnosis of IgA Nephropathy :  
     Presently, a renal biopsy is required for the accurate diagnosis of IgA nephropathy. It 
seems likely that in the not too distant future, a non-invasive diagnosis of IgA 
nephropathy will be possible. This will likely come from an extension of current studies 
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showing increased levels of under-galactosylated IgA1 in the circulation [156].Urinary 
proteomics also shows great promise for non-invasive diagnosis of IgAN [157]. 
      However, even if an accurate and reliable means of non-invasively diagnosing IgA 
nephropathy emerges, renal biopsy will remain as an important tool for rational decision 
making with regards to treatment and perhaps also for prognosis. 
 
Prognostication in IgA Nephropathy :  
      Use of new tissue markers of prognosis, such as those which can be obtained by 
special immunohistochemical studies for examining deposition of specific proteins (such 
as fibroblast specific protein-1), in-situ hybridization studies for cytokine expression, 
microdissection for mRNA and RNAi expression and studies of infiltration of renal tissue 
with immune cells carrying specific markers (such as GMP-17+ T cells) may overtake 
the conventional approach. This new wave of “modern” renal pathology will likely 
replace the older approaches to morphology and will offer new avenues for more accurate 
prognostication based on tissue biopsy,even in “early” disease before progression to renal 
insufficiency has occurred [158]. Urinary markers of progressive disease are also likely 
to be increasingly described and validated [159]. 
 
 
Treatment of IgA Nephropathy :  
    While real progress has no doubt been made, in terms of reducing the rate of 
progression of disease, no therapy for IgA nephropathy is truly “curative.” Eventually 
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palliative therapy must give way to more effective modification of the fundamental 
disease processes, based on specific molecular or cellular events (so-called “designer” 
drug therapy). It is also very probable that pharmaco-genomics will make significant 
modification to the therapeutic approaches to IgA nephropathy in the not too distant 
future. 
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Aims
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AIM : 
 
To assess the efficacy of mycophenolic  acid (MPA) in improving renal function and 
reducing proteinuria in high risk primary IgA nephropathy (IgAN) patients. 
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Abbreviations used : 
IgA N – Immunoglobulin A Nephropathy 
MPA – Mycophenolic acid 
MAP – Mean arterial pressure 
ACE-I – Angiotensin converting enzyme inhibitor 
ARB – Angiotensin receptor blocker 
e GFR – Estimated glomerular filtration rate 
Abb. MDRD – Abbreviated modification of diet in renal disease formula 
TDM – Therapeutic drug monitoring 
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Patients and methods
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PATIENTS AND METHODS :  
 
Inclusion criteria :  
 Patients with biopsy confirmed IgA Nephropathy (based on presence of predominant 
mesangial IgA deposits)  and who have any one of the following features were deemed 
to be at high risk of progression –  
    1. Mean arterial pressure ≥ 107 mm Hg 
    2. eGFR at presentation < 60 ml/min/1.73 m2 (Abb. MDRD) 
    3. Proteinuria > 3 gm/day 
    4. Glomerulosclerosis ≥ 50% on renal biopsy 
 
Exclusion criteria :  
1. Age < 12 years 
2. Secondary causes of IgA Nephropathy like liver diseases etc. 
3.Henoch Schonlein nephritis 
 
 
This is both a prospective and retrospective study wherein biopsy proven IgA 
Nephropathy patients who were diagnosed at CMC Hospital were identified from our 
renal biopsy records (2003 to 2009) and those at high risk of progression were identified 
based on the above criteria (from OPD charts and investigations from our computer 
database in case of retrospective patients) . Patients who were biopsied before 2008 were 
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identified from records whereas those enrolled from 2008-09 were prospectively 
followed. 
       Such patients who were treated with mycophenolic acid with steroids and 
antihypertensives and who had atleast 3 months of followup (MPA group) were 
compared with historical controls taken from an earlier published study from our 
institution [160]. Dose of mycophenolic acid was started at 30 mg per kg body weight 
and subsequently adjusted according to therapeutic drug monitoring(TDM) (6 hour area 
under curve) which is done in our Clinical pharmacology department. Regarding MPA, it 
is questionable whether standard dose therapy is the best way to treat a patient, given the 
large inter-individual variability in pharmacokinetics[162]. Several studies have shown a 
correlation between MPA exposure and efficacy[163]. Neumann et al. reported on the 
value of measuring MPA plasma concentrations in patients with autoimmune 
diseases[164]. The same may hold true in IgAN although it was not studied. Hence, we 
used TDM in determining MPA dose. 
     Steroids were started at 1mg per kg body weight on alternate days and continued for 3 
months following which they were tapered gradually by 10 mg reductions on alternate 
days until they were stopped. Doses of antihypertensives including angiotensin 
converting enzyme inhibitors/angiotensin receptor blockers wherever possible were 
adjusted according to the target blood pressures which is <130/80 mm Hg .  
 
         2 groups of controls were taken, first being that  treated with steroids and 
antihypertensives (steroid group), second group being that treated with antihypertensives 
only (no steroid group) i. e. without any immunosuppression. All the details including 
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history, clinical examination and laboratory parameters were recorded as per the 
proforma. 
     
                   All patients were analysed at the end of 3 months follow up with regard to 
proteinuria and renal function expressed in terms of serum creatinine and.eGFR 
(estimated glomerular filtration rate by Abbrd. MDRD formula). Only patients who could 
complete treatment without any interruptions due to non compliance or side effects 
requiring dose reduction were taken for analysis .  
                   Continuous data was presented as mean +/- SD unless otherwise specified. 
Comparison of continuous variables was done by the t test or Mann whitney U test where 
appropriate. SPSS software 15 was used for statistical analysis. p value < 0.05  was 
considered as significant . 
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Proforma
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PROFORMA 
 
Name :                                                                 Hosp. No. :  
Age :                               Sex : M / F                   Ph. No. : 
Presentation : 
    Preceding infection : Y / N             Sore throat : Y / N                                                            
    G .I .Infection : Y / N                     Other infection : 
    Nephrotic syndrome :  Y / N 
    Acute nephritis : Y / N 
    Nephritic-nephrotic : 
    Recurrent macrohematuria : Y / N 
    Uremic symptoms/Renal failure : Y / N 
    Rapidly progressive renal failure : Y / N 
    Systemic hypertension : Y / N 
    Malignant hypertension : Y / N 
    Incidentally diagnosed : Y / N 
    Duration of symptoms :  
 
Clinical features : 
    Blood pressure :                                  Mean arterial pressure : 
    Pedal edema : Y / N               Ht(cm) :           Wt(kg) :        BMI : 
    C.V.S. : 
    R.S : 
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    P/A : 
    C.N.S : 
Follow up : Y / N                                    Duration of follow up :  
 
Investigations : 
 
  At pres.   3 mon.     6 mon.   Last f/u 
Urine RBC’s     
24 hr up or 
up/uc 
    
B. Urea 
 
    
S. Creat. 
 
    
S. Uric acid 
 
    
S. Chol. 
 
    
S. Trigly. 
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   At pres.    3 mon    6 mon.  Last f/u. 
S.Total prot.(g/dl/) 
 
    
S.Alb(g/dl) 
 
    
GFR(ml/min/1.73m2) 
 
    
% Diff. in GFR 
 
    
    
 
Date of biopsy :                                      Biopsy No. : 
 
Hass staging of pathology : 
   Global sclerosis : Absent / <50% / >50%  
   Mesangial involvement : Absent / Mild / Moderate - Severe 
   Interstitial involvement : Absent / Mild / Moderate - Severe 
   Interstitial fibrosis : Absent / Mild / Moderate - Severe 
   Vascular involvement : Absent / Mild / Moderate - Severe 
   Tubular atrophy : Absent / Mild / Moderate – Severe 
 
   Ig A Deposits :                        Ig G Deposits :  
   Ig M Deposits :                        C 3 Deposits : 
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 Degree of crescents : Absent / Mild / Moderate – Severe 
 
 Drug therapy :  MMF / MMS + one of the following -  
 
     1. Fish oil + ACE -I 
     2. CRF Management  
     3. Steroid + Fish oil + ACE –I 
     4. Fish oil + Anti HTN 
     5. Steroid 
 
6 HR. MPA AUC : 
      
    At pres.      3 mon.        6 mon.       Last f/u 
    
  
 
Side effects of MMF :  
      Diarrhea : Y / N                            Leukopenia : Y / N 
      Infection : Y / N                            Focus of infection : 
      Other side effects : 
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Status after treatment : 
 
       0 - No follow up 
 
       1 - Presenting with GFR <85 and >20 % progression 
 
       2 - Presenting with GFR <85 and <20 % progression 
 
       3 - Presenting with GFR >85 and >20 % progression 
 
       4 - Presenting with GFR >85 and <20 % progression 
 
Renal survival :      1 - Yes 
                               2 - No at presentation  
                               3 - No at follow up 
GFR decrease in ml/min : 
Mode of RRT :       0 - No RRT 
                                1 - HD 
                                2 – CAPD 
                                3 - Transplant  
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Master chart
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Description of terms used in master chart :  
 
Hosp No . – Hospital number given to a patient at the time of registration 
Age – Age of the patient 
Sex – 1 – male 
          2 – female 
Meanartp – Mean arterial pressure 
Up24hrs – 24 hour urine protein at baseline 
Screat – Serum creatinine at baseline 
Gfr – Estimated glomerular filtration rate at baseline 
Up24h3 – 24 hour urine protein at 3 months followup 
Screa3 - Serum creatinine at 3 months followup 
Gfr3 - Estimated glomerular filtration rate at 3 months followup 
Globscle – 0 – Absent 
                  1 – Mild (<50%) 
                  2 – Moderate (>50%) 
Group – 1 – Case 
              2 – Control 1 
              3 – Control 2 
Up_abd – Absolute difference in 24 hour urine protein between 3 months followup and at 
baseline 
Up_ppd - Difference in percentage in 24 hour urine protein between 3 months followup 
and at baseline 
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Sc_apd - Absolute difference in serum creatinine between 3 months followup and at 
baseline 
Sc_ppd - Difference in percentage in serum creatinine between 3 months followup and at 
baseline 
Gfr_abd - Absolute difference in e GFR between 3 months followup and at baseline 
Gfr_ppd - Difference in percentage in e GFR between 3 months followup and at baseline 
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Sno Age Sex meanartp up24hrs screat gfr up24h3 screa3 gfr3 globscle group up_apd up_ppd sc_apd sc_ppd gfr_apd gfr_ppd 
1 33 1 97 0.6 1.9 37.4 2.1 1.5 57.29 2 1 1.51 255.93 -0.4 -21.05 19.89 53.18 
2 43 1 120 2 2.6 28.8 1.1 2.1 36.8 2 1 -0.9 -45 -0.5 -19.23 8 27.78 
3 43 2 97 3.8 2 29 1.9 1.7 34.86 1 1 -1.9 -50 -0.3 -15 5.86 20.21 
4 50 2 109 1.3 2.5 21.6 0.62 1.4 42.3 0 1 -0.68 -52.31 -1.1 -44 20.7 95.83 
5 22 1 107 1.2 1.7 53.8 0.39 1.7 53.8 2 1 -0.81 -67.5 0 0 0 0 
6 38 1 140 3.3 2 39.9 0.36 1.6 51.7 2 1 -2.94 -89.09 -0.4 -20 11.8 29.57 
7 36 1 97 1.2 2.8 27.3 0.11 2.3 34.3 2 1 -1.09 -90.83 -0.5 -17.86 7 25.64 
8 44 1 99 2.2 1.9 41.1 4.8 1.5 54 2 1 2.6 118.18 -0.4 -21.05 12.9 31.39 
9 25 1 87 1.2 1.8 49.1 0.5 1.5 60.6 2 1 -0.7 -58.33 -0.3 -16.67 11.5 23.42 
10 28 1 97 5.3 5.6 13.15 3.44 3.8 20.5 2 1 -1.86 -35.09 -1.8 -32.14 7.35 55.89 
11 24 2 120 3.2 2.2 29.15 0.38 2.3 27.7 2 1 -2.82 -88.13 0.1 4.55 -1.45 -4.97 
12 21 1 110 4 2.6 33.28 . 2.6 33.28 2 1 . . 0 0 0 0 
13 32 1 93 3.1 3.9 19.14 1.3 2.6 30.5 2 1 -1.8 -58.06 -1.3 -33.33 11.36 59.35 
14 39 1 97 2.3 1.6 51.4 0.93 1.9 42.15 . 1 -1.37 -59.57 0.3 18.75 -9.25 -18 
15 37 1 113 0.4 2.9 26.16 0.45 2.3 34.2 . 1 0.05 12.5 -0.6 -20.69 8.04 30.73 
16 32 1 . 0.1 2 41.36 0.09 1.6 53.5 . 1 -0.01 -10 -0.4 -20 12.14 29.35 
17 33 1 107 1.3 4.8 15 0.3 3.5 21.5 2 1 -1 -76.92 -1.3 -27.08 6.5 43.33 
18 45 2 . 2.4 2 28.64 1.7 1.7 34.54 2 1 -0.7 -29.17 -0.3 -15 5.9 20.6 
19 21 2 97 0.6 1.7 40.32 0.08 2 33.43 1 1 -0.52 -86.67 0.3 17.65 -6.89 -17.09 
20 37 1 110 4.4 2 40.16 0.02 1.5 55.9 1 1 -4.38 -99.55 -0.5 -25 15.74 39.19 
21 34 2 110 4.2 2.1 28.65 0.56 2.4 24.5 2 1 -3.64 -86.67 0.3 14.29 -4.15 -14.49 
22 41 1 . 1.8 2.5 30.4 0.74 1.8 44.4 0 1 -1.06 -58.89 -0.7 -28 14 46.05 
23 33 1 133 2.3 3.2 23.9 0.96 3 25.7 1 1 -1.31 -57.71 -0.2 -6.25 1.8 7.53 
24 24 2 117 2.5 3 20.4 . 2.9 21.2 2 1 . . -0.1 -3.33 0.8 3.92 
25 34 1 93 2.7 1.6 52.8 1.6 1.5 56.9 2 1 -1.1 -40.74 -0.1 -6.25 4.1 7.77 
26 35 1 130 7.3 6.8 38.4 1.2 1.8 45.9 . 1 -6.1 -83.56 -5 -73.53 7.5 19.53 
27 30 1 93 6 2.4 34 2.7 1.9 44.5 1 1 -3.3 -55 -0.5 -20.83 10.5 30.88 
28 41 1 . 2.1 1.6 50.8 0.06 1.4 59.4 2 1 -2.04 -97.14 -0.2 -12.5 8.6 16.93 
29 38 1 107 1 1.5 55.7 1.4 1.4 60.3 1 1 0.44 45.83 -0.1 -6.67 4.6 8.26 
30 38 1 107 1.9 2.8 27 0.78 2.1 38 2 1 -1.12 -58.95 -0.7 -25 11 40.74 
31 30 1 107 9.7 2.4 34 4 2.3 35.7 1 1 -5.7 -58.76 -0.1 -4.17 1.7 5 
32 48 1 103 1.9 2.2 34 1 2 38 1 1 -0.9 -47.37 -0.2 -9.09 4 11.76 
33 35 1 93 5.9 1 90.4 0.9 1 90.4 0 1 -5 -84.75 0 0 0 0 
34 30 1 110 8.1 3.1 25.3 5.8 2 42 2 1 -2.3 -28.4 -1.1 -35.48 16.7 66.01 
35 30 2 137 1.8 1.1 62 0.5 1.1 62 1 1 -1.3 -72.22 0 0 0 0 
36 38 1 143 3.8 2.4 32.4 3.4 2.4 32.4 2 1 -0.4 -10.53 0 0 0 0 
37 22 1 93 2.3 2 44.6 0.2 2.4 36 1 1 -2.1 -91.3 0.4 20 -8.6 -19.28 
38 41 1 94 1.7 2.8 26.7 1.57 1.9 41.7 2 1 -0.13 -7.65 -0.9 -32.14 15 56.18 
39 34 1 97 2.3 3.3 23 0.6 3 26 2 1 -1.7 -73.91 -0.3 -9.09 3 13.04 
40 29 2 117 3.3 2.5 24.2 0.97 2.4 25.4 . 1 -2.33 -70.61 -0.1 -4 1.2 4.96 
41 47 1 97 0.7 1.8 43.2 0.3 1.8 43.2 1 1 -0.4 -57.14 0 0 0 0 
42 33 2 97 3.1 3 19.19 2 2.6 59.4 1 2 -1.1 -35.48 -0.4 -13.33 40.21 209.54 
43 40 2 83 1.7 1.2 54.25 0.528 1.2 52.88 1 2 -1.17 -68.94 0 0 -1.37 -2.53 
44 37 2 93 1.6 1.1 59.3 1.1 1.1 59.4 1 2 -0.5 -31.25 0 0 0.1 0.17 
45 38 1 97 1.5 3.5 20.9 0.82 1.9 42.38 0 2 -0.68 -45.33 -1.6 -45.71 21.48 102.78 
46 64 1 97 4.7 1.7 45.13 . 5 12.48 2 2 . . 3.3 194.12 -32.65 -72.35 
47 50 1 100 7.9 1.9 40.02 5.6 1.9 40.08 1 2 -2.3 -29.11 0 0 0.06 0.15 
48 27 1 140 1.8 1.1 85.2 0.07 1 95.27 1 2 -1.73 -96.11 -0.1 -9.09 10.07 11.82 
49 16 1 100 5.5 0.6 188.4 0.18 0.7 159.89 1 2 -5.32 -96.73 0.1 16.67 -28.51 -15.13 
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50 14 1 91 3.6 0.8 135.2 0.49 0.5 242.24 0 2 -3.11 -86.39 -0.3 -37.5 107.04 79.17 
51 21 2 103 1.8 3.8 15.3 6.2 5.7 12.08 2 2 4.4 244.44 1.9 50 -3.22 -21.05 
52 42 2 117 2.4 3.3 16.27 1.8 4.3 12.01 2 2 -0.6 -25 1 30.3 -4.26 -26.18 
53 24 1 113 7.7 2.4 35.47 2.9 2 43.85 1 2 -4.8 -62.34 -0.4 -16.67 8.38 23.63 
54 32 1 111 0.9 1.1 82.32 0.8 1 92.04 1 2 -0.1 -11.31 -0.1 -9.09 9.72 11.81 
55 33 1 133 20.7 4.6 15.69 2.1 1.2 74.11 1 2 -18.6 -89.86 -3.4 -73.91 58.42 372.34 
56 42 1 117 1.3 3.6 19.83 0.88 2.1 37 1 2 -0.42 -32.31 -1.5 -41.67 17.17 86.59 
57 65 1 107 7.7 0.9 89.86 1.4 0.9 90.01 0 2 -6.3 -81.82 0 0 0.15 0.17 
58 26 1 110 4.3 1.1 85.86 3.2 1.2 77.79 1 2 -1.1 -25.58 0.1 9.09 -8.07 -9.4 
59 16 1 103 3.6 1.6 61.49 3.1 1 105.94 0 2 -0.5 -13.89 -0.6 -37.5 44.45 72.29 
60 45 2 104 4.2 1.2 69.47 3.1 1.2 51.63 1 2 -1.1 -26.19 0 0 -17.84 -25.68 
61 27 2 93 0.4 4.4 12.77 0.06 3.6 24.28 1 2 -0.37 -85.95 -0.8 -18.18 11.51 90.13 
62 35 2 97 4.7 1.7 45.13 0.29 1.2 54.34 2 2 -4.41 -93.83 -0.5 -29.41 9.21 20.41 
63 46 1 111 3.5 1.1 76.47 0.94 1 85.5 0 2 -2.56 -73.14 -0.1 -9.09 9.03 11.81 
64 26 1 114 3.6 2.3 36.65 0.11 1.9 45.77 2 2 -3.49 -96.94 -0.4 -17.39 9.12 24.88 
65 20 1 97 12.8 1.6 58.7 2.4 1.4 68.67 1 2 -10.4 -81.25 -0.2 -12.5 9.97 16.98 
66 18 1 96 8.2 1.5 64.68 6.8 2.1 43.94 1 2 -1.4 -17.07 0.6 40 -20.74 -32.07 
67 35 2 98 5.9 1.1 59.98 6.9 1.1 60 1 2 1 16.95 0 0 0.02 0.03 
68 35 1 86 3 1.7 48.91 2.9 1.3 66.77 1 2 -0.1 -3.33 -0.4 -23.53 17.86 36.52 
69 45 2 95 0.2 4.8 10.41 3.4 2.5 28.64 0 2 3.16 1340.68 -2.3 -47.92 18.23 175.12 
70 19 2 114 6.4 0.8 98.05 3.5 1 68.7 2 2 -2.9 -45.31 0.2 25 -29.35 -29.93 
71 60 2 116 0.8 1.5 37.59 . 2 30.9 2 2 . . 0.5 33.33 -6.69 -17.8 
72 31 1 118 18 2.1 39.28 0.18 1.1 83 0 2 -17.82 -99 -1 -47.62 43.72 111.3 
73 25 1 109 0.7 2.8 29.44 2.5 5 15.1 1 3 1.84 277.64 2.2 78.57 -14.34 -48.71 
74 76 1 113 0.4 1.5 48.28 0.39 1.9 36.82 1 3 -0.06 -12.36 0.4 26.67 -11.46 -23.74 
75 25 1 107 2.7 4 19.51 0.5 1.6 56.26 0 3 -2.2 -81.48 -2.4 -60 36.75 188.36 
76 30 2 107 4.3 4.5 12.18 0.38 5.4 9.88 2 3 -3.92 -91.16 0.9 20 -2.3 -18.88 
77 22 1 111 2.6 2.1 20.7 6.4 2.5 34.5 2 3 3.8 146.15 0.4 19.05 13.8 66.67 
78 31 1 107 4.4 2.3 19.6 2.5 2 41.63 1 3 -1.9 -43.18 -0.3 -13.04 22.03 112.4 
79 44 1 96 1.6 1.6 50.67 0.764 1.5 54.04 1 3 -0.84 -52.25 -0.1 -6.25 3.37 6.65 
80 25 1 110 1.6 1.6 56.18 1.2 1.8 49.11 1 3 -0.4 -25 0.2 12.5 -7.07 -12.58 
81 33 2 113 4.4 2.7 21.54 4.1 4.2 12.95 1 3 -0.3 -6.82 1.5 55.56 -8.59 -39.88 
82 40 1 97 1.2 1.6 51.05 0.625 1.5 55.09 0 3 -0.58 -47.92 -0.1 -6.25 4.04 7.91 
83 28 1 123 2.6 2.7 30.01 2.9 3.9 19.66 1 3 0.3 11.54 1.2 44.44 -10.35 -34.49 
84 39 1 106 5.9 2.7 28.06 3 3 24.88 2 3 -2.9 -49.15 0.3 11.11 -3.18 -11.33 
85 16 1 83 3.3 0.7 159.6 0.2 0.9 119.64 0 3 -3.1 -93.94 0.2 28.57 -39.96 -25.04 
86 24 1 133 2.7 1 96.61 0.16 0.8 126.23 0 3 -2.54 -94.07 -0.2 -20 29.62 30.66 
87 28 2 100 2.6 4.8 11.46 . 7.1 7.3 2 3 . . 2.3 47.92 -4.16 -36.3 
88 39 1 97 1.5 3.7 19.5 2.2 6.2 10.77 1 3 0.7 46.67 2.5 67.57 -8.73 -44.77 
89 51 2 116 2 3.4 15.11 0.39 2.8 18.93 1 3 -1.61 -80.5 -0.6 -17.65 3.82 25.28 
90 59 2 113 0.9 1.4 40.84 0.49 1.1 54.03 0 3 -0.44 -47.31 -0.3 -21.43 13.19 32.3 
91 43 1 107 5.8 3.1 23.45 4.8 2.6 28.78 2 3 -1 -17.24 -0.5 -16.13 5.33 22.73 
92 46 1 127 4.3 10.8 5.47 0.069 1.1 76.6 2 3 -4.23 -98.4 -9.7 -89.81 71.13 1300.37 
93 30 2 105 2.9 6.4 11 0.89 6.2 8.43 2 3 -2.01 -69.31 -0.2 -3.13 -2.57 -23.36 
94 44 2 105 2.5 3.9 15 0.6 1 93.61 2 3 -1.9 -76 -2.9 -74.36 78.61 524.07 
95 22 1 109 5.5 4.7 16.62 1.9 4.7 16.65 2 3 -3.6 -65.45 0 0 0.03 0.18 
96 48 1 104 0.9 1.7 45.87 1.5 1.4 57.49 2 3 0.6 66.3 -0.3 -17.65 11.62 25.33 
97 24 2 106 1.6 1.9 34.46 0.81 1.8 36.74 1 3 -0.79 -49.38 -0.1 -5.26 2.28 6.62 
98 32 1 116 2.2 3.9 19.11 2.1 1.7 49.89 1 3 -0.1 -4.55 -2.2 -56.41 30.78 161.07 
99 21 1 119 1.4 0.9 10.77 . 12.3 5.54 1 3 . . 11.4 1266.67 -5.23 -48.56 
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100 31 1 111 2.1 2.3 38.28 0.4 1.9 44.17 1 3 -1.7 -80.95 -0.4 -17.39 5.89 15.39 
101 37 1 97 4.6 1.7 48.36 0.78 1.2 72.41 1 3 -3.82 -83.04 -0.5 -29.41 24.05 49.73 
102 38 2 110 1.6 1.2 85 1.4 1.3 48.72 0 3 -0.2 -12.5 0.1 8.33 -36.28 -42.68 
103 35 1 113 4 1.7 48.91 0.95 2 40.61 0 3 -3.05 -76.25 0.3 17.65 -8.3 -16.97 
104 45 1 117 1.8 2.3 32.79 0.38 2 38.59 0 3 -1.42 -78.89 -0.3 -13.04 5.8 17.69 
105 27 1 120 2.2 3.6 21.53 1.3 9.8 6.8 2 3 -0.9 -40.91 6.2 172.22 -14.73 -68.42 
106 19 2 100 4.2 2.7 30.23 2.8 0.8 98.21 2 3 -1.4 -33.33 -1.9 -70.37 67.98 224.88 
107 15 1 86 1 1.4 59.56 0.76 1.4 72.8 1 3 -0.24 -24 0 0 13.24 22.23 
108 47 1 124 3.5 2.8 25.79 0.248 4.7 14.27 2 3 -3.25 -92.91 1.9 67.86 -11.52 -44.67 
109 26 1 124 5.3 3.1 26.18 3.2 3.6 20.65 2 3 -2.1 -39.62 0.5 16.13 -5.53 -21.12 
110 35 1 131 4.4 5.2 13.46 . 7 9.57 1 3 . . 1.8 34.62 -3.89 -28.9 
111 23 1 89 0.1 1.7 53.26 2 1.9 46.92 1 3 1.88 1552.89 0.2 11.76 -6.34 -11.9 
112 55 1 91 3.6 3.8 17.64 0.62 5.3 12.03 0 3 -2.98 -82.78 1.5 39.47 -5.61 -31.8 
113 31 1 111 1.5 1.3 67.88 0.26 1.4 62.8 1 3 -1.24 -82.67 0.1 7.69 -5.08 -7.48 
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RESULTS :  
 
Baseline characteristics : 
Table 1 summarizes the baseline details of the study population. 
The sample size in 3 groups is 41, 31 and 41 respectively . Baseline characteristics reveal 
a predominantly younger population with a mean age of  34.5 years in MPA group ,34.3 
and 34.4 in control groups respectively, the difference among the groups is not 
significant. 
     Sex distribution is favouring males with the ratio being 3.5:1 , 1.6:1 and 3.1:1 in the 3 
groups . 
   Mean arterial blood pressure at baseline is 107.5 mm Hg , 104.9 and 108.9 mm Hg in 
the 3 groups. 
    Median 24 hour urine protein excretion is 2.3 gm,3.6 gm and 2.6 gm in the 3 groups. 
    Median serum creatinine is 2.2 mg%, 1.6 and 2.7 mg% in the groups. 
    Median e GFR is 33.3 , 48.9 and 29.5 ml/min/1.73m2 BSA respectively in the MPA , 
steroid and no steroid group , the difference among MPA group and steroid group being 
significant. 
Global sclerosis : The percentage of patients with global sclerosis is 61.1% ,22.6% and 
34.1% respectively in MPA ,steroid and no steroid groups. The differences were 
statistically significant. 
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                                                TABLE 1 – Baseline characteristics 
   Variables      MPA     Steroid  No steroid           p 
    Age 34.5 ± 7.6 34.3 ± 13.7 34.4 ± 12.6 
MPA vs Ster:0.92 
MPA vs  
No ster:0.949 
   Sex(M:F) 3.5:1 1.6:1 3.1:1 
0.125 
0.797 
    MAP 107.5 ± 14.5 104.9 ± 12.7 108.9 ± 11.5 
0.43 
0.65 
  Proteinuria 
(gm/24 hrs)† 
2.3 
(1.3 - 3.8) 
3.6 
(1.7 - 6.4) 
2.6 
(1.5 - 4.3) 
0.049 
0.728 
  S.Creatinine† 
2.2 
(1.9 - 2.8) 
1.6 
(1.1 - 3.0) 
2.7 
(1.6 - 3.8) 
0.021 
0.305 
  eGFR† 
33.3 
(26.4 - 42.3) 
48.9 
(20.9 - 76.6) 
29.5 
(19.3 - 48.7) 
0.038 
0.344 
Global sclerosis   
no./(%) 
22/61.1% 
 (n=36) 
7/22.6% 
(n=31) 
14/34.1% 
(n=41) 
0.003 
0.023 
† - Median ( 25 – 75 th percentile) 
 
 
Outcomes : Table 2 
After 3 months of followup , outcomes depicted as percentage change were as follows. 
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Proteinuria – 
             MPA group – 58.8 % reduction in proteinuria when compared to baseline. 
             Steroid group – 45.3%  reduction in proteinuria when compared to baseline . 
             No steroid group – 48.5% reduction in proteinuria when compared to baseline. 
    The  changes in proteinuria were not statistically significant with the p values being 
0.55 for MPA vs steroid group and 0.31 for MPA vs no steroid group.            
 
                                                 TABLE 2 - Outcomes 
 
  Variables    MPA   Steroid   No steroid     p  
  % change in    
proteinuria 
-58.8 
(-83.5 to -
35.1) 
 (n=39) 
-45.3 
(-86.2 to -
21.0) 
(n=29) 
-48.5 
(-81.1 to -
12.5) 
(n=38) 
MPA vs Ster :0.55 
MPA vs No ster:0.31 
  % change in 
eGFR 
16.9 
(0.0 to 35.3) 
(n=41) 
11.6 
(-9.6 to 72.0) 
(n=31) 
-8.2 
(-28.6 to 24.9)
(n=41) 
0.58 
0.004  
 % change in 
S.Creatinine 
-12.5 
(-2.3 to - 0.5) 
(n=41) 
-9.1 
(-29.4  to 9.1)
(n=31) 
7.7 
(-17.5 to 31.6)
(n=41) 
0.50 
0.005 
MAP mmHg(at 
3 months) 
101.4 ± 11.5 
(n=36) 
100.1 ± 9.3 
(n=14) 
104.2 ± 11.0 
(n=25) 
0.67 
0.34 
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Renal function :  
      There is 16.9 % improvement in e GFR after 3 months of treatment in MPA group 
when compared to baseline vs  11.6 % in steroid group although it is not statistically 
significant (p =0.58 ) .In the ‘no steroid’ group, there is 8.2% reduction in e GFR which 
is statistically significant when compared to MPA group ( p = 0.004). Changes in serum 
creatinine showed similar trends which is given in table 2. 
      After 3 months of followup , wherever data is available , the mean blood pressure 
recordings in 3 groups is not significantly different (table 2). 
 
Subgroup analysis :  
ACE-I inhibitors : 
Since variable number of patients in all 3 groups received ACE-I/ARB’s , subgroup 
analyses is done to see the effect of ACE-I/ARB’s. Number of patients in each group are 
as follows : MPA Group – 31 
                         Steroid group – 17 
                         No steroid group – 24 
  
Baseline characteristics were given in table 3. As to baseline details regarding age, mean 
arterial pressure, proteinuria, serum creatinine and e GFR , there is no statistical 
significant difference between the groups. 
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           Table 3 – Baseline characteristics among ACE-I subgroup 
 
Variables MPA Steroid No steroid p value 
Age 34.52±7.93 30.88±12.63 36.29±14.53 0.34 
MAP 105.78±13.78 106.34±13.19 106.34±11.88 0.98 
Proteinuria(gm/24 
hrs)† 
2.3 
(1.20-3.80) 
3.5 
(1.65-6.15) 
1.7 
(1.05-3.52) 
0.25 
S.Creatinine† 2.0 
(1.70-2.50) 
1.6 
(1.10-2.80) 
1.7 
(1.42-2.70) 
0.213 
eGFR† 37.40 
(28.80-50.80) 
58.86 
(28.81-79.53) 
47.15 
(29.63-53.42) 
0.224 
† - Median (25 th to 75 th percentile) 
 
Outcomes – Table 4 
After 3 months of followup, there is 58.8 % reduction in proteinuria in MPA group 
whereas it is 35.1% and 47.6% in steroid and no steroid groups respectively. Regarding 
renal function, e GFR is better by 19.5%,11.6% and 3.25 in the 3 groups respectively and 
the difference  reached statistical significance when MPA group is compared to no 
steroid group. 
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                   Table 4 – Outcomes among ACE-I subgroup 
Variables MPA Steroid No steroid p value 
% change in 
proteinuria 
-58.83 
(-87.03 to -
37.85) 
-35.16 
(-85.10 to -
5.33) 
-47.61 
(-81.24 to -
12.39) 
MPA vs steroid 
:0.258 
MPA vs No 
steroid :0.18 
% change in 
eGFR 
19.53 
(0.00 to 30.88) 
11.63 
(-21.07 to 
72.01) 
3.22 
(-22.17 to 
24.47) 
0.787 
0.02 
% change in 
S.Creatinine 
-14.29 
(-20.83 to  
0.00) 
-9.09 
(-37.50 to 
27.65) 
-2.63 
(-17.27 to 
24.47) 
0.854 
0.02 
 
SIDE EFFECTS : 
A total of 2 patients in MPA group had diarrhea which did not require drug 
discontinuation but only dose modification. 2 patients had pyoderma. Other patients 
tolerated the drug reasonably well without any significant side effects.  
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Discussion
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       IgA Nephropathy has a rapid progression in Indian population with renal survival of 
only 35% at 10 years after onset of symptoms whereas the survival was 80% in case of 
Caucasian population [160] . Trials to test therapies which slow the rate of progression 
are needed to tackle this common glomerulonephritis . 
       There are only a small number of trials using MMF in IgAN. Chen et al. compared 
the use of MMF 0.5–0.75 g twice daily with prednisone 30–40mg daily in 62 Chinese 
patients with IgAN (30 with >72 weeks follow-up) and showed a benefit with respect to 
serum creatinine  and proteinuria [135] .  
      In 2005, Tang  et al published a prospective study in 40 Chinese patients with IgAN 
and mild tubulointerstitial lesions who were randomized 1:1 to 1.5 (BW < 60 kg) or 2.0 
g/day MMF for six months or continuation of contemporaneous medication only after 
blockade of the renin-angiotensin system failed to reduce proteinuria to < 1 g/d. Twelve 
months after stopping MMF, the overall remission rate (proteinuria < 0.3 g/d or 50% of 
baseline) was significantly higher in MMF-treated patients whose proteinuria dropped to 
62% of baseline, whereas urine protein in control patients increased to 120% of 
baseline[137] . 
        Maes et al. randomized 34 IgAN patients in Belgium to either MMF 2 g daily or 
placebo. After 3 years of follow-up, no significant differences in serum creatinine or 
proteinuria were found, although the study probably lacks sufficient power [136]. 
        Another study which took patients of Ig A Nephropathy with moderately advanced 
renal failure with a mean creatinine of 2.4 mg% and assessed the role of 1 year of MMF 
treatment was prematurely terminated because the interim analysis done by the 
independent study monitor revealed a trend towards a worse outcome in the MMF group 
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that would have made it very unlikely eventually to show a benefit for MMF given their  
rate of recruitment and their target sample size [138] . 
    Our study shows that in primary IgA Nephropathy patients at high risk of progression, 
treatment with mycophenolic acid in addition to steroids and antihypertensives led to a 
significant improvement in renal function when compared to antihypertensives alone and 
a trend towards better renal function is observed when compared to steroids plus 
antihypertensives. With regard to proteinuria,there is no significant difference with MPA 
treatment when compared to other 2 groups . 
    We took a population of IgAN with a fairly advanced disease as shown by the high 
mean serum creatinine of 2.2 mg% (vs creatinine of 1.6 mg% in the steroid group)and 
presence of global sclerosis in 61.1 % of the study population in the MPA group(vs 
22.6% and 34.4% in steroid and no steroid groups respectively) which was much higher 
than steroid group. Although to start with, renal function was worse in the MPA 
treatment arm with significant chronicity, at the end of follow up, there was a 16.9% 
improvement in e GFR and this was higher than the 11.6 % increase in steroid group 
although this did not reach statistical significance. A small sample size may have 
precluded statistical significance. However , the increase was statistically significant 
when compared to the ‘no steroid’ group.  
     Our results are at variance with previous studies [136,138] which showed that MPA 
was not beneficial in Ig A Nephropathy. Previous studies suggest that MMF is efficacious 
in Chinese population whereras at the same time, MMF is documented to be of no use in 
Caucasian population. Whether this variability in response depending on the ethnicity 
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explains partly the encouraging response in our Indian population is highly speculative. 
This needs to be studied further.  
      Certain factors in our study need to be considered . The small sample size of our 
study may have precluded definite conclusions. Short followup duration says that these 
results were only suggestive of a benefit and further randomized studies with a large 
sample size and long term followup need to be planned. 
      The results could have been influenced by the fact that variable number of patients 
received ACE-I/ARB’s in the 3 groups. Hence, a subgroup analysis was done among 
those patients who received ACE-I/ARB’s in the 3 groups.The results showed a similar 
trend as that of entire cohort and this goes on to say that the benefit achieved in MPA 
group is not due to ACE-I/ARB’s alone. 
        Most of our patients tolerated MPA. 2 patients had diarrhea which required dose 
modification and another 2 had pyoderma. None of them were discontinued on MPA. 
        Based on the encouraging results in this case-control study, a randomized study 
comparing steroids in 1 arm to mycophenolic acid and steroids in other arm along with 
ACE-I(in both arms) and with a follow up of atleast 5 years would give further insight as 
to the role of  MPA. 
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Conclusions
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CONCLUSIONS : 
 
1. In high risk primary IgA Nephropathy , 
      -  Combination of mycophenolic acid with steroids and antihypertensives led to a 
significant improvement in renal function when compared to antihypertensives alone and  
-  there was a trend towards better renal function when compared to steroids with 
antihypertensives. 
     2. With regard to proteinuria,there is no significant difference with mycophenolic acid  
treatment when compared to antihypertensives with or without steroids. 
     3. Whether ethnicity variation in response to mycophenolic acid favours Indian 
population needs to be studied. 
     4. Mycophenolic acid is well tolerated in our population with acceptable side effects. 
     5. Randomized controlled trials in this area of clinical research are urgently needed. 
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